

CITATION REPORT

List of articles citing

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

DOI: 10.1056/nejmoa1504627

New England Journal of Medicine, 2015, 373, 123-35.

Source: <https://exaly.com/paper-pdf/61184513/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2253	Current state of immunotherapy for non-small cell lung cancer. 2017 , 6, 196-211		107
2252	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. 2017 , 6, 169-177		2
2251	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. 2017 , 6, 186-195		8
2250	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. 2017 , 6, 220-229		9
2249	Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). 2017 , 6, 159-168		24
2248	Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. 2017 , 6, 113-118		11
2247	Special topics in immunotherapy and radiation therapy: reirradiation and palliation. 2017 , 6, 119-130		10
2246	Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. 2015 , 10, 1685-93		38
2245	Expanding the peptidome for immunotherapy. 2015 , 126, 1154-6		0
2244	Immune Checkpoint Blockade in Hepatocellular Carcinoma. 2015 , 4, 201-7		36
2243	FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. 2015 , 1, 15049		29
2242	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. 2015 , 7, 15-8		42
2241	Radiation with immunotherapy: an emerging combination for cancer treatment. 2015 , 4, 331-338		5
2240	Nivolumab ist nach platinhaltiger Primärtherapie wirksamer als Docetaxel. 2015 , 18, 28-30		
2239	INVITED ABSTRACTS. 2015 , 10, S66-S172		4
2238	[Molecular tumour therapy]. 2015 , 56, 1389-400; quiz 1401-2		3
2237	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. 2015 , 17, 1020-9		37

2236 Neue Hoffnung beim fortgeschrittenen Plattenepithelkarzinom der Lunge. **2015**, 18, 30-31

2235 Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. **2015**, CD010341 17

2234 Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. **2015**, 4, 34 18

2233 An update on current standards and clinical trials in systemic therapy for stage III NSCLC. **2015**, 4, 289-297

2232 From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. **2015**, 21, 413-24 2

2231 Immunotherapy for Advanced Lung Cancer. **2015**, 21, 383-91 6

2230 Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. **2015**, 35, 963-76 140

2229 Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. **2015**, 27, 482-8 24

2228 Pulmonary Lung Cancer Subspecialty Training. **2015**, 22, 281-5 0

2227 Chemotherapy for Advanced-Stage Non-Small Cell Lung Cancer. **2015**, 21, 366-70 35

2226 Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions. **2015**, 21, 450-64 30

2225 Status quo in der Zweitlinientherapie des NSCLC und Ausblick in die Zukunft. **2015**, 38, I-VI

2224 The Evolution of Therapies in Non-Small Cell Lung Cancer. **2015**, 7, 1815-46 81

2223 The distinctive nature of adenocarcinoma of the lung. **2015**, 8, 2399-406 12

2222 Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. **2015**, 7, 2397-414 51

2221 Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells. **2015**, 6, 633 9

2220 Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?. **2015**, 9, 5641-53 21

2219 Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer. **2015**, 9, 5491-7 1

2218	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. 2015 , 8, 2949-57	6
2217	Immunotherapy in Tumors. 2015 , 112, 809-15	25
2216	RNA-Based Vaccines in Cancer Immunotherapy. 2015 , 2015, 794528	113
2215	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. 2015 , 34, 313-21	26
2214	New & Emerging Drugs for Squamous Cell Lung Cancer. 2015 , 05,	
2213	Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer. 2015 , 121, 3562-3	3
2212	Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. 2015 , 3, 1292-8	21
2211	Immunotherapy: the third wave in lung cancer treatment. 2015 , 3, 923-4	2
2210	Checkpoint inhibitors in bladder and renal cancers: results and perspectives. 2015 , 7, 1259-71	16
2209	Immunotherapy for Head and Neck Squamous Cell Carcinoma. 2015 , 29, 1033-43	22
2208	Évaluation de la réponse à la chimiothérapie, aux thérapies ciblées et à l'immunothérapie. 2015 , 7, 455-461	
2207	Cancers bronchiques non à petites cellules métastatiques ou réarrangés : de la première à la huitième ligne. 2015 , 7, 497-505	
2206	BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. 2015 , 10, 1396-403	57
2205	Potential Therapeutic Targets in Triple Negative Breast Cancer. 2015 , 7, 215-223	1
2204	Immunothérapie dans le cancer bronchique : les inhibiteurs de Checkpoints. 2015 , 7, 353-360	
2203	Comment offrir à tous un accès aux thérapies innovantes ?. 2015 , 7, 462-475	0
2202	Indications de réanimation en oncologie thoracique. 2015 , 7, 545-553	1
2201	Traitement de 1re ligne des cancers bronchopulmonaires non à petites cellules de stade IV en l'absence d'addiction oncogénique. 2015 , 7, 404-413	

2200 Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. **2015**, 7, 232-241

2199 Combination cancer immunotherapy and new immunomodulatory targets. **2015**, 14, 561-84 806

2198 Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. **2015**, 16, 897-907 314

2197 New immunotherapies targeting the PD-1 pathway. **2015**, 36, 587-95 120

2196 Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. **2015**, 20, 1127-34 23

2195 Evolving synergistic combinations of targeted immunotherapies to combat cancer. **2015**, 15, 457-72 447

2194 Lung cancer: Squiring immunotherapy to CheckMate. **2015**, 12, 436 5

2193 Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. **2015**, 14, 1507-18 40

2192 The role of immunotherapy in oncology. **2015**, 11, 2861-4

2191 PD-L1 expression as a potential predictive biomarker. **2015**, 16, 1285-7 75

2190 Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2015**, 373, 1627-39 59.2 5964

2189 PD-1 and PD-L1 blockade in gastrointestinal malignancies. **2015**, 41, 893-903 44

2188 Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. **2015**, 26, 2375-91 828

2187 Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. **2015**, 3, 1344-55 197

2186 Bone metastases in lung cancer. Potential novel approaches to therapy. **2015**, 192, 799-809 18

2185 Immunothérapie anticancer : les molécules immunomodulatrices en développement clinique. **2015**, 17, 379-389

2184 Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*, **2015**, 373, 1803-13 59.2 3725

2183 Immune checkpoints and immunotherapy for colorectal cancer. **2015**, 3, 289-97 61

2182	Immunomodulation: checkpoint blockade etc. 2015 , 17 Suppl 7, vii26-vii31	18
2181	Overcoming Resistance to Targeted Therapies in Cancer. 2015 , 42, 896-908	31
2180	Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer. 2015 , 72, 1851-5	14
2179	AACR Cancer Progress Report 2015. 2015 , 21, S1-128	27
2178	A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer. 2015 , 76, 793-801	10
2177	Nivolumab: a review in advanced squamous non-small cell lung cancer. 2015 , 75, 1925-34	16
2176	AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. 2015 , 8, 96	62
2175	Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. 2015 , 113, 1343-9	38
2174	Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic. 2015 , 42 Suppl 2, S19-28	16
2173	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. 2015 , 41, 914-24	33
2172	U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy. 2015 , 20, 1320-5	20
2171	Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. 2015 , 42 Suppl 2, S11-8	47
2170	Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. 2015 , 16, 2601-13	17
2169	Congr�s de lâssociation amricaine de recherche contre le cancer �AACR 2015. 2015 , 17, 277-298	
2168	Immunogicit�de la chimioth�apie. 2015 , 17, 345-353	
2167	CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. 2015 , 14, 1303-11	19
2166	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 2015 , 33, 3488-515	363
2165	A broad-spectrum integrative design for cancer prevention and therapy: The challenge ahead. 2015 , 35 Suppl, S1-S4	28

2164	Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results. 2015 , 75, 1757-71	11
2163	New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. 2015 , 16, 49	25
2162	Breast cancer and immunology: biomarker and therapeutic developments. 2015 , 15, 1215-22	9
2161	[Nivolumab, a new hope in non-small cell lung cancer]. 2015 , 102, 1046-52	2
2160	Progress in lung cancer: ASCO 2015. 2015 , 24, 367-8	2
2159	Nivolumab for treating non-small cell lung cancer. 2015 , 15, 1789-97	19
2158	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. 2015 , 7, 1169-86	35
2157	Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. 2015 , 7, 1213-27	71
2156	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. 2015 , 41, 868-76	280
2155	Tremelimumab for the treatment of malignant mesothelioma. 2015 , 15, 1819-29	17
2154	Battling regional (stage III) lung cancer: bumpy road of a cancer survivor in the immunotherapy age. 2016 , 2016,	1
2153	Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance. 2016 , 129, 879-80	3
2152	The Paradox of Anti-cancer Agents and Recurring Emergence of Drug Resistance. 2016 , 05,	
2151	Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. 2016 , 8, E1348-E1350	
2150	Immuno-oncology. 2016 ,	
2149	[Application of immunomodulatory therapeutic antibodies - a new perspective in oncology]. 2016 , 157 Suppl 2, 9-16	1
2148	Immuntherapie bei Lungenkrebs. 2016 , 3, 60-68	
2147	The steady progress of targeted therapies, promising advances for lung cancer. 2016 , 10, 638	6

2146	Antibody Therapy. 2016 , 550-559	0
2145	Immuno-oncology combinations: raising the tail of the survival curve. 2016 , 13, 171-93	67
2144	Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. 2016 , 7, 52810-52817	250
2143	Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope. 2016 , 11, 87-92	1
2142	Contemporary Treatment of Metastatic Renal Cell Carcinoma. 2016 , 10, 295	29
2141	Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. 2016 , 7, 32113-28	81
2140	Immune checkpoint inhibition in patients with brain metastases. 2016 , 4, S9	27
2139	Fundamental effects of PD-1 antibody on the body: a brief report. 2016 , 9, 4137-41	3
2138	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. 2016 , 9, 5855-5866	8
2137	A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. 2016 , 9, 7275-7283	36
2136	Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?. 2016 , 10, 293	38
2135	Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?. 2016 , 13, 157-70	60
2134	Genetic alteration profiling of patients with resected squamous cell lung carcinomas. 2016 , 7, 36590-36601	18
2133	Targeted therapies and immunotherapy in non-small-cell lung cancer. 2016 , 10, 648	20
2132	Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings. 2017 , 10, 153-163	19
2131	-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. 2017 , 10, 101-112	43
2130	Combined modality therapy for thoracic and head and neck cancers: a review of updated literature based on a consensus meeting. 2016 , 102, 459-471	8
2129	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. 2016 , 9, 3187-95	11

2128	New targeted treatments for non-small-cell lung cancer - role of nivolumab. 2016 , 10, 103-17	18
2127	Lung cancer in Brazil: epidemiology and treatment challenges. 2016 , 7, 141-148	10
2126	Pneumonitis with Nonspecific Interstitial Pneumonia Pattern Caused by Nivolumab in a Patient with Metastatic Melanoma. 2016 , 06,	
2125	Immunobiology of Tumors and Advances in Immunotherapy. 2016 , 07,	
2124	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. 2016 , 1,	52
2123	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability . PD-L1. 2016 , 7, 771-788	61
2122	Treatment of Lung Cancer in Medically Compromised Patients. 2016 , 35, e484-91	2
2121	Biomarkers for Immunotherapy: Current Developments and Challenges. 2016 , 35, e493-503	61
2120	Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away. 2016 , 35, 281-90	8
2119	Immunoproteasomes and immunotherapy-a smoking gun for lung cancer?. 2016 , 8, E558-63	5
2118	Adjuvant immunotherapy in resected early non-small cell lung cancer-battle lost, hopefully not the war!. 2016 , 8, 1886-90	1
2117	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. 2016 , 5, 628-636	12
2116	Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?. 2016 , 5, 538-542	4
2115	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. 2016 , 5, 720-726	24
2114	Non-Small-Cell Lung Cancer Treatment. 2016 , 62, 7-12	1
2113	Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases. 2016 , 8, E535-7	14
2112	The role of surgical intervention in lung cancer with carcinomatous pleuritis. 2016 , 8, S901-S907	7
2111	Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer. 2016 , 8, E1254-E1256	

2110	Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer. 2016 , 2016, 1745108	14
2109	Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. 2016 , 2016, 9839685	15
2108	Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. 2016 , 2016, 2138627	18
2107	Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). 2016 , 205, 418-424	20
2106	How the lab is changing our view of colorectal cancer. 2016 , 102, 541-547	9
2105	Toxicity management of immunotherapy for patients with metastatic melanoma. 2016 , 4, 272	73
2104	PharmaForum. 2016 , 39, 401-404	
2103	Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers. 2016 , 7, 1599-1604	7
2102	High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. 2016 , 6, 1629-40	138
2101	An update on clinical oncology for the non-oncologist. 2016 , 14, 294-9	
2100	Neither the maximum tumor size nor solid component size is prognostic in part-solid lung cancer: to be ground-glass opacity or not to be, is that really the question?. 2016 , 8, 2334-2336	3
2099	Monitoring of the Immune Dysfunction in Cancer Patients. 2016 , 4,	11
2098	Harnessing the immune system to improve cancer therapy. 2016 , 4, 261	167
2097	Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. 2015 , 6, 663	63
2096	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. 2016 , 7, 550	282
2095	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. 2016 , 7, 621	90
2094	Focus on Alectinib and Competitor Compounds for Second-Line Therapy in -Rearranged NSCLC. 2016 , 3, 65	4
2093	Focus on Nivolumab in NSCLC. 2016 , 3, 67	3

2092	Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. 2016 , 6, 233	94
2091	Recent Advances in Immunotherapy in Metastatic NSCLC. 2016 , 6, 239	23
2090	Advances in Cancer Immunotherapy in Solid Tumors. 2016 , 8,	109
2089	The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy. 2016 , 17, 286	4
2088	The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. 2016 , 17,	24
2087	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. 2016 , 17,	93
2086	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. 2016 , 17,	41
2085	Immunotherapy for Gastroesophageal Cancer. 2016 , 5,	35
2084	Cytotoxic and Pro-Apoptotic Effects of Cassane Diterpenoids from the Seeds of <i>Caesalpinia sappan</i> in Cancer Cells. 2016 , 21,	23
2083	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. 2016 , 4, 13	131
2082	[Plastic Surgery in Palliative Care - Report on the Consensus Workshop of the 37th Annual Meeting of the German-language Group for Microsurgery of the Peripheral Nerves and Vessels (DAM) 2016 in Bochum]. 2016 , 48, 340-345	
2081	PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. 2016 , 11, e0160485	25
2080	A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways. 2016 , 11, e0167397	4
2079	A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma. 2016 , 11, 167-73	11
2078	Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. 2016 , 10, 3153-3161	19
2077	The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials. 2016 , 9, 5867-5874	14
2076	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. 2016 , 7, 484-9	81
2075	PD-L1 expression in human cancers and its association with clinical outcomes. 2016 , 9, 5023-39	370

2074	Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. 2016 , 9, 5101-16	26
2073	Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. 2016 , 12, 807-16	7
2072	Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. 2016 , 9, 3711-26	71
2071	PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. 2016 , 9, 489-502	40
2070	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. 2016 , 7, 74350-74361	31
2069	Radiation therapy and the abscopal effect: a concept comes of age. 2016 , 4, 118	51
2068	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. 2016 , 4, 215	6
2067	Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. 2016 , 4, 268	13
2066	The challenge of developmental therapeutics for adrenocortical carcinoma. 2016 , 7, 46734-46749	15
2065	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. 2016 , 7, 73068-73079	60
2064	Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma. 2016 , 22, 17-22	13
2063	The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration. 2016 , 22, 96-100	4
2062	Immune Checkpoint Therapy in Head and Neck Cancers. 2016 , 22, 108-16	10
2061	Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. 2016 , 22, 130-7	29
2060	Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives. 2016 , 28, 104-9	13
2059	Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives. 2016 , 28, 150-8	5
2058	Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. 2016 , 98, 114-117	99
2057	Pembrolizumab (Keytruda). 2016 , 12, 2777-2789	127

2056	Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. 2016 , 21, 974-80	52
2055	Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. 2016 , 8, 809-19	39
2054	Immunothérapie : un nouveau paradigme dans la prise en charge du cancer bronchique non ^ petites cellules. 2016 , 18, 365-370	1
2053	Place des antiangiogéniques dans le traitement des cancers du poumon. 2016 , 18, 409-418	1
2052	Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. 2016 , 122, 3024-31	56
2051	Metabolic programming in chronically stimulated T cells: Lessons from cancer and viral infections. 2016 , 46, 1574-82	7
2050	Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC). 2016 , 39, 202-4	25
2049	Immune Checkpoint Therapy in Non-Small Cell Lung Cancer. 2016 , 22, 81-91	7
2048	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. 2016 , 22, 68-72	26
2047	Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. 2016 , 98, 51-58	81
2046	Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors. 2016 , 40, 1133-42	62
2045	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. 2016 , 34, 596-603	35
2044	Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. 2016 , 8, 1079-85	124
2043	Irradiation and immunotherapy: From concept to the clinic. 2016 , 122, 1659-71	55
2042	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives. 2016 , 138, 2549-61	119
2041	Immune-mediated respiratory adverse events of checkpoint inhibitors. 2016 , 28, 269-77	33
2040	Rare side-effects of checkpoint inhibitors. 2016 , 28, 295-305	6
2039	Chemotherapy-sparing treatment strategies for follicular lymphoma: current options and future directions. 2016 , 23, 371-6	

2038	Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. 2016 , 2, 1346-1353	493
2037	Low density of CD204-positive M2-type tumor-associated macrophages in Epstein-Barr virus-associated gastric cancer: a clinicopathologic study with digital image analysis. 2016 , 56, 74-80	20
2036	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. 2016 , 34, 2969-79	322
2035	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. 2016 , 34, 2980-7	338
2034	Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer. 2016 , 34, 2953-5	11
2033	Novel Targets and Their Assessment for Cancer Treatment. 2016 , 163-180	
2032	Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. 2016 , 99, 123-6	35
2031	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. 2016 , 29, 1165-72	269
2030	Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. 2016 , 46, 875-8	61
2029	Immunotherapy for genitourinary cancer: state of the art and new perspectives. 2016 , 27, 585-99	4
2028	Ocular and orbital side-effects of checkpoint inhibitors: a review article. 2016 , 28, 288-94	82
2027	The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy. 2016 , 100, 212-4	19
2026	Immune-Related Adverse Events From Immune Checkpoint Inhibitors. 2016 , 100, 242-51	66
2025	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. 2016 , 5, e1186323	2
2024	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. 2016 , 14, 255-64	272
2023	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. 2016 , 14, 1213-1224	73
2022	Measurement of quality of life in second-line patients with advanced NSCLC without targetable mutations: a review. 2016 , 5, 105-116	1
2021	A stochastic model for immunotherapy of cancer. 2016 , 6, 24169	22

2020	Immunotherapy for breast cancer: past, present, and future. 2016 , 35, 525-546	27
2019	AACR Cancer Progress Report 2016. 2016 , 22 Suppl 19, S1-S137	27
2018	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. 2016 , 17, e542-e551	842
2017	The cost and value of cancer drugs - are new innovations outpacing our ability to pay?. 2016 , 5, 40	12
2016	Les inhibiteurs des points de contrôle immunitaire dans le cancer bronchique non à petites cellules de stade avancé. 2016 , 103 Suppl 1, S138-S143	0
2015	Biomarqueurs prédictifs de réponse aux traitements bloquant les voies de costimulation inhibitrices. 2016 , 103 Suppl 1, S151-S159	4
2014	Performance Status-Based Oncology Practice Guidelines: Easier Said Than Done. 2016 , 12, 597-9	
2013	Immunotherapy for Lung Cancer. 2016 , 39, 360-8	9
2012	Cancer immunotherapy trials: leading a paradigm shift in drug development. 2016 , 4, 42	28
2011	High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer. 2016 , 12, 1422-1428	10
2010	Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma. 2016 , 43, 219-26	16
2009	Biochemistry of Oxidative Stress. 2016 ,	3
2008	Overview and management of toxicities of immune checkpoint-blocking drugs. 2016 , 7, 28-37	1
2007	Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. 2016 , 15, 67	96
2006	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). 2016 , 4,	78
2005	A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. 2016 , 1, 16025	25
2004	Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. 2016 , 8, 1363-1369	28
2003	Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. 2016 , 8, 1437-1446	19

2002	Immune checkpoint inhibitors renal side effects and management. 2016 , 8, 1417-1425	8
2001	Renal effects of immune checkpoint inhibitors. 2017 , 32, 936-942	48
2000	Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. 2016 , 11, 2048-2050	34
1999	Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease. 2016 , 5, e109	22
1998	Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. 2016 , 6, 31726	169
1997	Emerging therapeutic agents for lung cancer. 2016 , 9, 138	65
1996	A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma. 2016 , 1, 379-385	3
1995	MicroRNA-profiles in lung adenocarcinomas. 2016 , 1, 469-474	
1994	Colite induite par les inhibiteurs de checkpoint immunitaire : anticorps anti-CTLA-4 et anticorps anti-PD-1/PDL-1. 2016 , 18, 501-508	1
1993	Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. 2016 , 14, 173	77
1992	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. 2016 , 6, 25952	29
1991	Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. 2016 , 10, 336-342	8
1990	A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. 2016 , 95, e5539	30
1989	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. 2016 , 16, 434	93
1988	Rationale of an economically driven PD1 biomarker development in lung cancerâ€”an academic dilemma. 2016 , 9, 109-110	1
1987	For Advanced Cancer, What Treatment Is Next?. 2016 , 116, 50-3	1
1986	Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma. 2016 , 1, 75-81	7
1985	Immune Therapy for Prostate Cancer. 2016 , 22, 334-341	10

1984	Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors. 2016 , 39, 367-372	61
1983	A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. 2016 , 26, 469-80	25
1982	Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials. 2016 , 95, e4611	36
1981	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. 2016 , 4, 84	72
1980	Traitement de seconde ligne et au-delà des cancers bronchopulmonaires non à petites cellules de stade IV en l'absence d'addiction oncogénique. 2016 , 8, 361-372	
1979	Les populations particulières : les personnes âgées atteintes d'un cancer bronchique. 2016 , 8, 404-410	
1978	Prise en charge des métastases cérébrales des carcinomes bronchiques. 2016 , 8, 425-433	
1977	Indications de réanimation en oncologie thoracique. 2016 , 8, 506-514	
1976	Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases. 2016 , 4, 80	64
1975	Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of non-small cell lung carcinomas using fine-needle aspiration cases. 2016 , 54, 8-16	11
1974	Learning from the "tsunami" of immune checkpoint inhibitors in 2015. 2016 , 101, 213-20	30
1973	The State of Lung Cancer Research: A Global Analysis. 2016 , 11, 1040-50	105
1972	Immune checkpoint inhibitors in lung cancer: past, present and future. 2016 , 12, 1151-63	24
1971	Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. 2016 ,	2
1970	Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. 2016 , 33, 44	31
1969	Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. 2016 , 5, e1169356	23
1968	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. 2016 , 16, 895-901	15
1967	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. 2016 , 9, 47	221

1966	Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. 2016 , 48, 428-439	26
1965	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?. 2016 , 8, 681-6	1
1964	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. 2016 , 76, 925-45	100
1963	Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. 2016 , 68, 287-291	188
1962	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. 2016 , 22, 4585-93	655
1961	Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. 2016 , 27, 1706-12	71
1960	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. 2016 , 17, 31	47
1959	Inhibitory immunologicznych punktów kontrolnych podziału komórki w leczeniu chorób nowotworowych. 2016 , 47, 155-162	1
1958	Beyond monotherapy: Integrating immunotherapy into current treatment regimens. 2016 , 11, S8-S9	
1957	PD-L1 Expression in Lung Cancer. 2016 , 11, 964-75	201
1956	Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer. 2016 , 76, 969-78	19
1955	Targeting T Cell Co-receptors for Cancer Therapy. 2016 , 44, 1069-78	314
1954	Combinatorial Cancer Immunotherapies. 2016 , 130, 251-77	75
1953	Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. 2016 , 4, 563-8	199
1952	Targeting PD-L1 for non-small-cell lung cancer. 2016 , 8, 747-58	10
1951	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. 2016 , 2, 1179-86	123
1950	Targeting K-Ras cancers. 2016 , 11, S9-S10	
1949	Endocrinological side-effects of immune checkpoint inhibitors. 2016 , 28, 278-87	94

1948	Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. 2016 , 76, 3767-72	98
1947	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). 2016 , 27, 1492-504	280
1946	FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. 2016 , 21, 643-50	223
1945	[Anticancer drugs: Which prices for therapeutic innovations?]. 2016 , 103, 361-7	2
1944	Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer. 2016 , 34, 879-81	34
1943	Into the Clinic With Nivolumab and Pembrolizumab. 2016 , 21, 527-8	10
1942	Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective. 2016 , 140, 245-8	9
1941	Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. 2016 , 140, 249-54	69
1940	Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). 2016 , 96, 1-6	26
1939	Management of lung cancer. 2016 , 44, 244-248	1
1938	Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases. 2016 , 27, 1354-6	33
1937	Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer. 2016 , 77, 1031-8	9
1936	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. 2016 , 27, 1482-92	335
1935	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. 2016 , 16, 275-87	1444
1934	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. 2016 , 16, 989-1004	9
1933	TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. 2016 , 76, 2087-93	55
1932	The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. 2016 , 22, 1865-74	421
1931	Emerging Opportunities and Challenges in Cancer Immunotherapy. 2016 , 22, 1845-55	172

1930	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. 2016 , 60, 210-25	391
1929	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. 2016 , 60, 190-209	412
1928	Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. 2016 , 95, 663-72	22
1927	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. 2016 , 37, 7507-14	32
1926	Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell. 2016 , 37, 8515-28	34
1925	Understanding dendritic cell immunotherapy in ovarian cancer. 2016 , 16, 643-52	5
1924	Thymic malignancies: Moving forward with new systemic treatments. 2016 , 46, 27-34	4
1923	Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. 2016 , 60, 12-25	240
1922	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. 2016 , 27, 1286-91	64
1921	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. 2016 , 9, 34	189
1920	Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?. 2016 , 17, 350-361	83
1919	Development of amino- and dimethylcarbamate-substituted resorcinol as programmed cell death-1 (PD-1) inhibitor. 2016 , 88, 50-8	11
1918	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. 2016 , 21, 634-42	274
1917	Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. 2016 , 17, 25	13
1916	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016 , 374, 2542-52	59.2 828
1915	Immune checkpoint inhibition in ovarian cancer. 2016 , 28, 339-48	96
1914	Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. 2016 , 140, 341-4	98
1913	Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. 2016 , 6, e411	12

1912	The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. 2016 , 114, 1145-51	22
1911	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. 2016 , 48, 607-16	613
1910	The Prognostic Significance of pSTAT1 and CD163 Expressions in Surgically Resected Stage 1 Pulmonary Squamous Cell Carcinomas. 2016 , 23, 3071-81	4
1909	Re-Evaluating Clonal Dominance in Cancer Evolution. 2016 , 2, 263-276	33
1908	Novel Therapies in Castration-Resistant Prostate Cancer. 2016 , 259-269	
1907	High co-expression of PD-L1 and HIF-1 α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. 2016 , 60, 125-35	71
1906	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. 2016 , 12, 2219-31	33
1905	A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. 2016 , 8, 665-74	30
1904	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. 2016 , 8, 583-600	52
1903	The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. 2016 , 16, 577-84	11
1902	Recent developments in the use of immunotherapy in non-small cell lung cancer. 2016 , 10, 781-98	23
1901	Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors. 2016 , 27, 1356-60	22
1900	Updates from the Neuro-Oncology Section of the 2015 American Neurological Association Annual Meeting. 2016 , 12, 143-7	1
1899	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. 2016 , 28, 373-82	108
1898	What's hot in lung cancer. 2016 , 37, 79-85	
1897	Medikamentöse Behandlung des Lungenkarzinoms – Grundlagen und neue Säulen der Therapie. 2016 , 45, 140-147	
1896	Roles of regulatory T cells in cancer immunity. 2016 , 28, 401-9	280
1895	Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis. 2016 , 1023-1024, 9-16	33

1894	Current Challenges in Cancer Treatment. 2016 , 38, 1551-66	318
1893	Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. 2016 , 28, 122-9	37
1892	Survival Analysis of Advanced Non-Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy. 2016 , 15, 467-477	8
1891	PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. 2016 , 5, e1131379	73
1890	Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab. 2016 , 8, 1163-7	9
1889	The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease. 2016 , 194, 644	4
1888	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. 2016 , 4, 48	145
1887	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. 2016 , 64, 587-600	24
1886	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. 2016 , 100, 77-84	70
1885	Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics. 2016 , 34, 3605-3608	52
1884	Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation. 2016 , 130, 397-411	10
1883	[Therapy of Metastatic Non-small Cell Lung Cancer]. 2016 , 70, 567-78	1
1882	A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. 2016 , 115, 784-8	10
1881	[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer]. 2016 , 72, 300-304	
1880	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. 2016 , 17, 1590-1598	450
1879	Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma. 2016 , 101, 111-119	8
1878	[Not Available]. 2016 , 103, S12-5	0
1877	[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma]. 2016 , 146 Suppl 1, 2-6	3

1876	[Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment]. 2016 , 146 Suppl 1, 25-9	3
1875	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. 2016 , 48, 1327-1329	84
1874	A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform. 2016 , 11, 1863-1868	65
1873	The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update. 2016 , 10, 1229-1241	9
1872	The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer. 2016 , 16, 1119-1129	1
1871	Longstanding Challenges in Lung Cancer: Are We Meeting Them?. 2016 , 28, 669-671	3
1870	The genomic landscape of breast cancer and its interaction with host immunity. 2016 , 29, 241-50	130
1869	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. 2016 , 17, 1497-1508	954
1868	Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. 2016 , 16, 744	81
1867	Metastatic Lung Cancer: Emerging Therapeutic Strategies. 2016 , 37, 736-749	1
1866	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. 2016 , 37, 771-782	8
1865	Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. 2016 , 37, 760-770	33
1864	Immune checkpoint inhibitors: a new class of anticancer drug. 2016 , 27, 23-28	1
1863	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. 2016 , 113, 11919-11924	127
1862	Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?. 2016 , 28, 726-731	6
1861	Divide and Conquer to Treat Lung Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1892-1893	59.2 12
1860	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016 , 375, 1856-1867	59.2 2647
1859	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. 2016 , 16, 1479-1489	10

1858	Genomic insights into head and neck cancer. 2016 , 1,	51
1857	Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials. 2016 , 32, 1927-1934	
1856	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. 2016 , 99, 79-87	85
1855	The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. 2016 , 16, 903-10	5
1854	Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. 2016 , 10, 444-54	18
1853	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. 2016 , 18, 59	28
1852	PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. 2016 , 8, 1081-9	24
1851	A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. 2016 , 8, 1011-9	28
1850	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. 2016 , 34, 677-684	22
1849	The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. 2016 , 63, 1490-1493	156
1848	Spatial Heterogeneity in the Tumor Microenvironment. 2016 , 6,	116
1847	The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. 2016 , 21, 910-21	42
1846	The Role of Molecular Diagnostics in the Management of Patients with Gliomas. 2016 , 17, 51	25
1845	Inflammation and cancer: tissue regeneration gone awry. 2016 , 43, 55-61	91
1844	[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. 2016 , 37, 557-567	31
1843	The Molecular Pathology of Lung Cancer. 2016 , 9, 353-78	17
1842	Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies. 2016 , 11, 1927-1939	42
1841	Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. 2016 , 21, 1230-1240	165

1840	Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. 2016 , 5, 2567-78	45
1839	Chemotherapy remains an essential element of personalized care for persons with lung cancers. 2016 , 27, 1829-35	52
1838	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. 2016 , 173, 1407-24	42
1837	The immune system and cancer evasion strategies: therapeutic concepts. 2016 , 279, 541-62	146
1836	Immunotherapy for lung cancer. 2016 , 21, 821-33	126
1835	PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. 2016 , 36, 317-34	57
1834	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. 2016 , 107, 107-15	22
1833	Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC. 2016 , 11, 1954-1961	8
1832	EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. 2016 , 9, 59	113
1831	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. 2016 , 34, 794-796	14
1830	Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. 2016 , 11, 1869-1878	66
1829	Lymphocyte-activation gene-3, an important immune checkpoint in cancer. 2016 , 107, 1193-7	115
1828	Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. 2016 , 99, 41-5	24
1827	Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry. 2016 , 65, 1317-1323	13
1826	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. 2016 , 11, 2066-2081	40
1825	Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. 2016 , 27, 1966-9	19
1824	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. 2016 , 4, 820-822	44
1823	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. 2016 , 4, 36	76

1822	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. 2016 , 388, 1002-11	113
1821	New and emerging targeted treatments in advanced non-small-cell lung cancer. 2016 , 388, 1012-24	299
1820	Treatment: Radiation Therapy. 2016 , 170, 105-18	12
1819	Current Progress in Immunotherapy for the Treatment of Biliary Cancers. 2016 , 47, 351-357	8
1818	Malignant Mesothelioma Effusions Are Infiltrated by CD3 T Cells Highly Expressing PD-L1 and the PD-L1 Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. 2016 , 11, 1993-2005	77
1817	Management of Lung Cancer in the Elderly. 2016 , 170, 251-84	8
1816	Multimodality Therapy for NSCLC. 2016 , 170, 151-63	5
1815	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. 2016 , 12, 1255-61	9
1814	Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harboring Targetable Oncogenic Driver Mutations. 2016 , 76, 1321-36	14
1813	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. 2016 , 11, 1387-96	6
1812	Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. 2016 , 76, 5994-6005	136
1811	PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1 and CD8 tumor-infiltrating T cells and outcome. 2016 , 29, 1552-1564	22
1810	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer: Implications for immunotherapy. 2016 , 5, e1213934	53
1809	Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?. 2016 , 89, 20160472	28
1808	Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. 2016 , 11, 2238-2240	101
1807	Cancer Immunotherapy by Checkpoint Blockade. 2016 , 561-580	
1806	PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?. 2016 , 27, 1658-9	3
1805	Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. 2016 , 27, 1953-8	195

1804	Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. 2016 , 27, 2117-2123	92
1803	Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. 2016 , 120, 185-94	72
1802	Direct-to-Consumer Drug Advertising in Oncology Is Not Beneficial to Patients or Public Health. 2016 , 2, 1397-1398	8
1801	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. 2016 , 122, 3344-3353	199
1800	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. 2016 , 22, 6051-6060	292
1799	Immunotherapy in Lung Cancer. 2016 , 170, 203-23	6
1798	Diagnosis and Molecular Classification of Lung Cancer. 2016 , 170, 25-46	84
1797	Lung Cancer Staging and Prognosis. 2016 , 170, 47-75	143
1796	PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. 2016 , 65, 52-60	80
1795	Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. 2016 , 5, 119-122	5
1794	Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. 2016 , 34, 538-547	28
1793	Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. 2016 , 4, 72	104
1792	Lung cancer in 2016: immunotherapy comes of age. 2016 , 4, 947-949	9
1791	Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. 2016 , 108, 164-174	93
1790	Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. 2016 , 11, 858-870	41
1789	Understanding immunotherapy for the treatment of non-small cell lung cancer. 2016 , 25, S12-7	1
1788	Lung Cancer Stem Cells. 2016 , 149-175	0
1787	BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. 2016 , 16, 2829-2837	226

1786	PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher. 2016 , 9, 939-49	9
1785	Novel immunotherapy in the treatment of advanced non-small cell lung cancer. 2016 , 9, 1571-1581	18
1784	Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. 2016 , 5, e1214788	97
1783	Update in Lung Cancer 2015. 2016 , 194, 661-71	10
1782	Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. 2016 , 49, 1099-107	15
1781	Current management and future directions in metastatic pancreatic adenocarcinoma. 2016 , 122, 3765-3775	14
1780	Reply: Disparities in Access to Lung Transplantation-More Than Meets the Eye. 2016 , 194, 643-4	
1779	Rapid bone repair in a patient with lung cancer metastases to the spine using a novel herbal medicine: A case report. 2016 , 12, 2023-2027	3
1778	Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. 2016 , 5, e1231292	70
1777	Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. 2016 , 67, 66-72	79
1776	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. 2016 , 8, 460-473	26
1775	A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer. 2016 , 100, 672-684	8
1774	Lung cancer: First-line immunotherapy in lung cancer - taking the first step. 2016 , 13, 595-6	3
1773	Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. 2016 , 152, 1128-1136	129
1772	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. 2016 , 34, 3740-3748	319
1771	Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. 2016 , 12, 1089-96	15
1770	Novel therapeutic targets on the horizon for lung cancer. 2016 , 17, e347-e362	120
1769	PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. 2016 , 58, 7-14	99

1768	Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. 2016 , 111, 577-591	26
1767	Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. 2016 , 11, 753-761	45
1766	Treatment of Stage IIIA Non-Small-Cell Lung Cancer: A Concise Review for the Practicing Oncologist. 2016 , 12, 601-6	10
1765	Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies. 2016 , 15, 412-9	15
1764	Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. 2016 , 99, 117-9	70
1763	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). 2016 , 130, 19-29	71
1762	Immunotherapy for head and neck squamous cell carcinoma. 2016 , 9, 66-69	20
1761	Management of non-small cell lung cancer in the era of personalized medicine. 2016 , 78, 173-179	18
1760	Drug discovery in advanced prostate cancer: translating biology into therapy. 2016 , 15, 699-718	77
1759	Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin-Expressing Cells. 2016 , 84, 191-3	7
1758	Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. 2016 , 22, 4550-5	55
1757	Immuntherapie des Lungenkarzinoms. 2016 , 13, 249-254	
1756	Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?. 2016 , 59, 50-57	18
1755	Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. 2016 , 99, 162-5	31
1754	Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. 2016 , 99, 148-50	41
1753	SCLC-State of the Art and What Does the Future Have in Store?. 2016 , 17, 325-333	34
1752	Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. 2016 , 30, 397-405	31
1751	Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. 2016 , 14, 662-81	33

1750	Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. 2016 , 34, 3204-12	35
1749	Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. 2016 , 16, 1209-23	14
1748	Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom. 2016 , 14, 662-83	36
1747	Optimal design and endpoint of clinical trials using immune checkpoint blocking agents. 2016 , 16, 1217-1218	2
1746	Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer. 2016 , 16, 1541-1547	2
1745	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. 2016 , 30, 571-584	66
1744	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. 2016 , 1, e000066	14
1743	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. 2016 , 4, 1038-1048	54
1742	FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. 2016 , 14, 238	22
1741	PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. 2016 , 5, e1254856	34
1740	Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. 2016 , 113, E7759-E7768	234
1739	Combination approaches in NSCLC involving immune checkpoint inhibitors. 2016 , 5, 163-171	1
1738	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. 2016 , 113, E7769-E7777	116
1737	A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. 2016 , 5, 3041-3050	30
1736	Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. 2016 , 34, 556-565	16
1735	Making urothelial carcinomas less immune to immunotherapy. 2016 , 34, 534-537	1
1734	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. 2016 , 8, 328rv4	1281
1733	Targeting the PD-1/PD-L1 axis in the treatment of lung cancer. 2016 , 7, 17-27	

1732	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. 2016 , 4, 60	46
1731	Immunothérapie et évaluation de la réponse tumorale : la difficulté de la pseudoprogression. 2016 , 18, 523-526	1
1730	Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1). 2016 , 18, 533-542	2
1729	Function of follicular helper T cell is impaired and correlates with survival time in non-small cell lung cancer. 2016 , 41, 1-7	20
1728	Diminished but not dead: chemotherapy for the treatment of NSCLC. 2016 , 17, 1464-1465	14
1727	The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. 2016 , 6, 32020	14
1726	Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. 2016 , 102, 44-48	55
1725	PD-L1 testing, fit for routine evaluation? From a pathologist's point of view. 2016 , 9, 201-206	28
1724	From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?. 2016 , 17, 59	3
1723	Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective. 2016 , 46, 1174-1178	3
1722	Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. 2016 , 10, 383-388	62
1721	Immune checkpoint inhibitors for cancer treatment. 2016 , 39, 1577-1587	29
1720	Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. 2016 , 27, 2242-2250	65
1719	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. 2016 , 102, 21-27	10
1718	Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. 2016 , 102, 65-73	61
1717	Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. 2016 , 17, 1213-1220	38
1716	Systemic Therapy for Metastatic Colorectal Cancer. 2016 , 275-338	
1715	Dendritic cell and cancer immune checkpoint. 2016 , 39, 468-472	0

1714	Current status of immunotherapy for non-small-cell lung cancer. 2016 , 102, 337-51	6
1713	Imaging Biomarkers in Immunotherapy. 2016 , 8, 1-13	24
1712	Highlights for ESMO 40: celebration review for lifetime achievement awards. 2016 , 1, e000010	
1711	Review of the British Thoracic Society Winter Meeting 2015, 2-4 December, London, UK. 2016 , 71, 555-9	
1710	Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet. 2016 , 2016, 223-5	5
1709	Programmed Death-1 Inhibition in Cancer With a Focus on Non-Small Cell Lung Cancer: Rationale, Nursing Implications, and Patient Management Strategies. 2016 , 20, 319-26	3
1708	Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. 2016 , 90, 280-8	7
1707	Immunotherapy for Lung Cancer: Many Questions Yet to Be Answered. 2016 , 14, 935-8	1
1706	Zielgerichtete und immunologische Therapie beim NSCLC. 2016 , 19, 56-62	
1705	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2016 , 27, v1-v27	590
1704	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" Napoli, December 5th 2015. 2016 , 4,	78
1703	Pseudo-Meigs' syndrome due to ovarian metastases from colon cancer: a case report and review of the literature. 2016 , 2, 112	1
1702	It's TIME for a biomarker-driven approach to cancer immunotherapy. 2016 , 4, 43	5
1701	Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. 2016 , 31, 238-42	1
1700	Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. 2016 , 16, 868	12
1699	Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. 2016 , 4, 34	18
1698	Vergleich zweier EGFR-Hemmer bei Patienten mit Plattenepithel-NSCLC. 2016 , 19, 31-32	
1697	Plattenepithel-NSCLC: Vergleich EGFR-Hemmer. 2016 , 8, 32-34	

1696	Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. 2016 , 2, e000321	33
1695	Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report. 2016 , 95, e5077	1
1694	Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management. 2016 , 26, 548-55	7
1693	Innovation in Bladder Cancer Immunotherapy. 2016 , 39, 291-7	4
1692	Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. 2016 , 22, 257-66	27
1691	Best Practices in Treatment Selection for Patients With Advanced NSCLC. 2016 , 23, 2-14	5
1690	Immunotherapy of Colorectal Cancer. 2016 , 39, 346-50	7
1689	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. 2016 , 43, 1954-61	87
1688	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. 2016 , 90, 638-47	353
1687	Immunotherapy for small-cell lung cancer. 2016 , 17, 846-847	6
1686	Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. 2016 , 9, 29	17
1685	Harnessing the antitumor immunity cycle to treat lung cancer. 2016 , 5, 40-48	
1684	Impact of genomic sequencing on precision medicine for clinical oncology. 2016 , 1, 255-265	
1683	Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer. 2016 , 17, e179-e183	4
1682	Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France. 2016 , 8, 999-1009	26
1681	Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. 2016 , 9, 411-7	72
1680	Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). 2016 , 98, 69-75	114
1679	Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. 2016 , 48, 20-4	90

1678	Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. 2016 , 22, 3025-36	80
1677	Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. 2016 , 21, 804-16	156
1676	A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. 2016 , 11, 1846-1855	67
1675	Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. 2016 , 28, e127-38	30
1674	Recent results of immunotherapy and perspectives for advanced NSCLC. 2016 , 5, 57-60	
1673	Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. 2016 , 11, 1879-1890	118
1672	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. 2016 , 43, 501-13	8
1671	Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. 2016 , 12, 1805-22	6
1670	Combinatorial approach to cancer immunotherapy: strength in numbers. 2016 , 100, 275-90	65
1669	Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. 2016 , 97, 73-80	96
1668	Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. 2016 , 98, 76-78	24
1667	[Stereotactic radiotherapy augments the immune response]. 2016 , 192, 70-1	2
1666	Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma. 2016 , 2, 1-18	2
1665	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. 2016 , 17, 976-983	666
1664	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. 2016 , 17, 883-895	783
1663	Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer. 2016 , 6, 20-23	19
1662	Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma. 2016 , 11, 432-3	28
1661	Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. 2016 , 22, 3713-7	49

1660	Novel Immunotherapeutic Approaches to the Treatment of Cancer. 2016,	1
1659	Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not. 2016, 97, 15-21	32
1658	Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study. 2016, 98, 84-90	4
1657	Nintedanib in NSCLC: evidence to date and place in therapy. 2016, 8, 188-97	17
1656	Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. 2016, 17, 391-397	43
1655	The Utility of Exercise Testing in Patients with Lung Cancer. 2016, 11, 1397-410	35
1654	"Pseudoprogession" of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy. 2016, 11, e117-9	26
1653	The use of biomarkers in the treatment of non-small cell lung cancer. 2016, 1, 25-36	2
1652	Targeted Therapy and Immunotherapy for Lung Cancer. 2016, 25, 601-9	56
1651	Epigenetic therapy in gastrointestinal cancer: the right combination. 2016, 9, 560-79	65
1650	Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. 2016, 2, 1217-22	165
1649	Immune Checkpoint Inhibitors in Older Adults. 2016, 18, 47	40
1648	Practice pearls in the management of lung cancer in the elderly. 2016, 7, 362-7	5
1647	Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma. 2016, 39, 353-8	5
1646	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. 2016, 1-39	
1645	Immunonkologische Therapiestrategien. 2016, 11, 22-29	
1644	Neoadjuvant Therapy in Non-Small Cell Lung Cancer. 2016, 25, 567-84	14
1643	Adjuvant Therapy for Stage I and II Non-Small Cell Lung Cancer. 2016, 25, 585-99	8

1642	Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress. 2016 , 12, 355-72	13
1641	Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. 2016 , 54, 507	44
1640	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. 2016 , 166, 9-29	22
1639	[Cancer immunotherapy: Rational and recent breakthroughs]. 2016 , 37, 694-700	22
1638	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. 2016 , 4, 3	146
1637	IL-15/sIL-15R α gene transfer suppresses Lewis lung cancer growth in the lungs, liver and kidneys. 2016 , 23, 54-60	10
1636	Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. 2016 , 37, 4251-61	62
1635	Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer. 2016 , 11, 324-33	24
1634	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. 2016 , 12, 551-64	7
1633	Current status of immunotherapy. 2016 , 46, 191-203	36
1632	Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. 2016 , 55, 7-14	129
1631	Modulation of tumor immunity: a patent evaluation of WO2015026684A1. 2016 , 26, 417-25	7
1630	New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy. 2016 , 14, 61-65	
1629	Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent. 2016 , 33, 13	10
1628	Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. 2016 , 12, 413-25	94
1627	Pembrolizumab for the treatment of non-small cell lung cancer. 2016 , 16, 397-406	52
1626	Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy. 2016 , 43, 104-12	46
1625	Epigenetic Therapeutics: A New Weapon in the War Against Cancer. 2016 , 67, 73-89	212

1624	Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. 2016 , 22, 2177-82	92
1623	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. 2016 , 387, 1540-1550	3964
1622	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. 2016 , 12, 57-75	39
1621	Prime time for immune-checkpoint targeted therapy at ASCO 2015. 2016 , 5, e1068494	5
1620	Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study. 2016 , 16, 165-7	4
1619	Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. 2016 , 65, 1-11	27
1618	The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. 2016 , 8, 479-88	105
1617	Best Lung Cancer Research, 2015. 2016 , 38, 1	
1616	CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. 2016 , 39, 98-106	1102
1615	Glioblastoma. 2016 , 134, 381-97	160
1614	Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung. 2016 , 21, 205-13	21
1613	How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. 2016 , 21, 233-43	45
1612	PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer. 2016 , 2, 569-570	5
1611	The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer. 2016 , 2, 571-572	14
1610	A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. 2016 , 17, 232-236.e1	103
1609	Immunotherapy for head and neck cancer: latest developments and clinical potential. 2016 , 8, 168-75	12
1608	2015 and human cancer: back to overall survival. 2016 , 12, 1751-4	
1607	Scientific Advances in Lung Cancer 2015. 2016 , 11, 613-638	164

1606	Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient. 2016 , 34, 1438-42	15
1605	Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. 2016 , 34, 1676-88	64
1604	Novel therapies for advanced squamous cell carcinoma of the lung. 2016 , 12, 659-67	8
1603	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. 2016 , 93, 59-68	87
1602	Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. 2016 , 12, 1045-58	7
1601	Immune checkpoint therapy for non-small-cell lung cancer: an update. 2016 , 8, 279-98	50
1600	Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. 2016 , 19, 630-44	46
1599	PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?. 2016 , 140, 351-4	11
1598	Personalized chemotherapy of lung cancer: What the radiologist should know. 2016 , 97, 287-96	8
1597	[Asbestos and respiratory diseases]. 2016 , 45, 117-32	2
1596	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. 2016 , 11, 469-77	31
1595	Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. 2016 , 20, 175-81	26
1594	Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. 2016 , 17, 169-76	15
1593	The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. 2016 , 17, 161-8	13
1592	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. 2016 , 7, 10501	846
1591	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. 2016 , 34, 987-1011	114
1590	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. 2016 , 45, 7-18	264
1589	The immune mechanisms of abscopal effect in radiation therapy. 2016 , 40, 10-24	94

1588	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. 2016 , 22, 2261-70	164
1587	Management of toxicities of immune checkpoint inhibitors. 2016 , 44, 51-60	522
1586	[Lung cancer and rheumatoid arthritis. An interdisciplinary challenge]. 2016 , 75, 47-53	2
1585	Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016 , 374, 493-4	59.2 37
1584	End-of-Life Preferences in Advanced Cancer Patients. 2016 , 19, 6	
1583	[PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. 2016 , 36, 94-102	5
1582	Immunonkologische Therapiestrategien. 2016 , 22, 30-39	
1581	[Pathological complete response: A predictive survival factor after neoadjuvant chemotherapy in lung cancer]. 2016 , 103, 66-72	5
1580	[2015 through the eyes of the Bulletin of Cancer editorial board]. 2016 , 103, 3-17	1
1579	Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. 2016 , 17, 299-308	435
1578	The race for combined checkpoint inhibition in NSCLC. 2016 , 17, 259-260	3
1577	Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?. 2016 , 140, 326-31	99
1576	TIME for a successful cancer vaccine in NSCLC?. 2016 , 17, 131-132	1
1575	Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. 2016 , 51, 850-2	44
1574	The management of immune-related adverse events associated with immune checkpoint blockade. 2016 , 1, 89-97	11
1573	The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. 2016 , 17, 18	14
1572	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. 2016 , 21, 462-73	190
1571	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. 2016 , 57, 91-103	95

1570	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. 2016 , 468, 511-25	172
1569	Tubulin inhibitors in non-small cell lung cancer: looking back and forward. 2016 , 17, 1113-29	18
1568	Die medikamentöse Therapie des metastasierten nicht-kleinzelligen Lungenkarzinoms. 2016 , 13, 65-74	
1567	Coinhibitory Pathways in Immunotherapy for Cancer. 2016 , 34, 539-73	507
1566	An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer. 2016 , 46, 1341-7	26
1565	[Issues and current limits for immunohistochemical assessment of PD-L1 status in bronchial biopsies]. 2016 , 103, 368-80	5
1564	Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research. 2016 , 22, 1907-13	39
1563	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. 2016 , 11, 524-36	32
1562	Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. 2016 , 101, 75-85	84
1561	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. 2016 , 13, 273-90	640
1560	Targeting Oral Cancer. 2016 ,	
1559	S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis. 2016 , 12, 701-13	4
1558	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. 2016 , 387, 1909-20	2308
1557	Targeted agents and combinations in ovarian cancer: where are we now?. 2016 , 16, 441-54	10
1556	Immunotherapy in Head and Neck Cancers. 2016 , 211-224	
1555	Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer. 2016 , 11, 976-88	161
1554	Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. 2016 , 4, 289-93	112
1553	Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCEVIH Working Group. 2016 , 27, 397-408	31

1552	A high number of IgG4-positive cells in gastric cancer tissue is associated with tumor progression and poor prognosis. 2016 , 468, 549-57	14
1551	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. 2016 , 98, 122-36	17
1550	Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer. 2016 , 16, 747-58	10
1549	Emerging immunotherapy for the treatment of esophageal cancer. 2016 , 25, 667-77	21
1548	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. 2016 , 387, 1837-46	1731
1547	PD-L1 in non-small-cell lung cancer: the third target for immunotherapy. 2016 , 387, 1795-6	9
1546	Adoptive T-Cell Therapy for Cancer. 2016 , 130, 279-94	126
1545	Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. 2016 , 15, 235-47	358
1544	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. 2016 , 10, 183-93	90
1543	Ocular toxicities of MEK inhibitors and other targeted therapies. 2016 , 27, 998-1005	51
1542	Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. 2016 , 45, 30-7	168
1541	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. 2016 , 8, 4-31	36
1540	Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers. 2016 , 16, 1-4	5
1539	Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets. 2016 , 13, 75-6	8
1538	Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. 2016 , 9, 419-28	21
1537	Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?. 2016 , 387, 1488-14908	
1536	Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. 2016 , 41, 207-14	18
1535	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. 2016 , 22, 793-801	43

1534	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. 2016 , 27, 559-74	548
1533	Prospects for gene-engineered T cell immunotherapy for solid cancers. 2016 , 22, 26-36	243
1532	Current progress in immunotherapy for pancreatic cancer. 2016 , 381, 244-51	120
1531	Prospects for the use of ipilimumab in treating advanced prostate cancer. 2016 , 16, 421-32	5
1530	Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. 2016 , 27, 590-9	28
1529	TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value. 2016 , 99, 63-73	52
1528	Immunosuppressive cells in tumor immune escape and metastasis. 2016 , 94, 509-22	168
1527	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. 2016 , 17, 212-223	110
1526	Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. 2016 , 5, e1094598	79
1525	Safety and efficacy of targeted agents monotherapy in advanced NSCLC. 2016 , 9, 143-55	1
1524	Macrophages, Inflammation, and Lung Cancer. 2016 , 193, 116-30	137
1523	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. 2016 , 9, 123-35	2
1522	Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis. 2016 , 22, 331-9	11
1521	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. 2016 , 27, 214-24	67
1520	Immunologic approaches to cancer prevention-current status, challenges, and future perspectives. 2016 , 43, 161-172	28
1519	Cancer Neoantigens and Applications for Immunotherapy. 2016 , 22, 807-12	146
1518	PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy. 2016 , 27, 206-7	17
1517	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. 2016 , 22, 609-20	254

1516	Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration. 2016 , 2, 118-22	41
1515	Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?. 2016 , 16, 1-5	7
1514	Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients. 2016 , 18, 33-9	10
1513	Precision oncology: A new era of cancer clinical trials. 2017 , 387, 121-126	42
1512	Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer. 2017 , 107, 50-58	34
1511	Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. 2017 , 17, 528-534	7
1510	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. 2017 , 24, 111-120	14
1509	Pulmonary sarcoid-like granulomatosis induced by nivolumab. 2017 , 176, 1060-1063	73
1508	Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. 2017 , 13, 195-207	381
1507	Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. 2017 , 103, e123-e125	4
1506	High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. 2017 , 104, 1-6	110
1505	Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer. 2017 , 104, 111-118	64
1504	Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. 2017 , 30, 530-538	68
1503	Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. 2017 , 33, 749-759	50
1502	[Perioperative therapies in surgical non N2 non-small cell lung cancer]. 2017 , 104, 79-85	1
1501	High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas. 2017 , 18, 504-511.e1	10
1500	Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. 2017 , 53, 128-137	91
1499	Renal complications of immune checkpoint blockade. 2017 , 41, 100-110	61

1498	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. 2017 , 3, 502-509	18
1497	Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?. 2017 , 29, 207-217	5
1496	Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. 2017 , 73, 1-8	279
1495	PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. 2017 , 17, 305-312	34
1494	Therapeutic Cancer Vaccines. 2017 , 47-78	1
1493	Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. 2017 , 106, 1-7	294
1492	Beyond platinum treatment for NSCLC: what does the future hold?. 2017 , 17, 293-295	7
1491	Targeting the Lung Cancer Microenvironment: Harnessing Host Responses. 2017 , 309-327	1
1490	Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. 2017 , 19, 4	12
1489	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. 2017 , 18, 295-304	10
1488	Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. 2017 , 174, 1-21	87
1487	Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy. 2017 , 35, 217-226	11
1486	T cell exhaustion: from pathophysiological basics to tumor immunotherapy. 2017 , 15, 1	116
1485	Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. 2017 , 19, 761-768	8
1484	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. 2017 , 5, 106-117	162
1483	Self-Assembled Bifunctional Peptide as Effective Drug Delivery Vector with Powerful Antitumor Activity. 2017 , 4, 1600285	26
1482	Glioblastoma. 2017 , 265-288	1
1481	Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy. 2017 , 4, e000163	6

1480	An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. 2017 , 12, 791-803	85
1479	Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. 2017 , 105, 17-22	36
1478	Radiotherapy and immunotherapy: a beneficial liaison?. 2017 , 14, 365-379	504
1477	Predicting the future from the past. 2017 , 49,	3
1476	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. 2017 , 18, 312-322	981
1475	Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials. 2017 , 18, 345-353.e5	14
1474	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. 2017 , 23, 3316-3324	28
1473	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. 2017 , 35, 157-165	268
1472	Targeting ALK: Precision Medicine Takes on Drug Resistance. 2017 , 7, 137-155	269
1471	Tailoring Palliative Care to the Changing Needs of People Facing Cancer. 2017 , 35, 813-815	9
1470	Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review. 2017 , 18, 444-459.e1	56
1469	Cardiovascular Toxicities Associated with Cancer Immunotherapies. 2017 , 19, 21	99
1468	[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]. 2017 , 37, 46-54	1
1467	Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. 2017 , 75, 141-149	66
1466	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. 2017 , 17, 387-394	89
1465	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. 2017 , 6, e1286437	21
1464	Upregulation of thioredoxin-1 in activated human NK cells confers increased tolerance to oxidative stress. 2017 , 66, 605-613	19
1463	[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. 2017 , 37, 61-78	10

1462	PD-1 and PD-L1 antibodies in cancer: current status and future directions. 2017 , 66, 551-564	188
1461	[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives]. 2017 , 37, 133-141	
1460	Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. 2017 , 38, 513-525	25
1459	Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition. 2017 , 6, e1274476	28
1458	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. 2017 , 18, 446-453	223
1457	MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential. 2017 , 6, e1280645	15
1456	Autoantibodies: Opportunities for Early Cancer Detection. 2017 , 3, 198-213	66
1455	PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. 2017 , 7, 44173	50
1454	Standard of care in immunotherapy trials: Challenges and considerations. 2017 , 13, 2164-2178	4
1453	Assays for PD-L1 Expression: Do All Roads Lead to Rome?. 2017 , 3, 1058-1059	4
1452	Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. 2017 , 22, 470-479	166
1451	Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma. 2017 , 13, 1097-1103	1
1450	Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials. 2017 , 26, 415-426	4
1449	The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly. 2017 , 17, 565-571	22
1448	The safety of second-line treatment options for non-small cell lung cancer. 2017 , 16, 471-479	2
1447	Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. 2017 , 139, 30-36	27
1446	Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. 2017 , 9, 261-272	24
1445	Looking back and to the future: 'Are we improving 'cure' in non-small cell lung cancer?. 2017 , 75, 192-194	10

1444	Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. 2017 , 92, 283-290	31
1443	Biomarkers and the 'target therapies' in oncology, research and business. 2017 , 11, 217-219	1
1442	Targeting the programmed death-1 pathway in lymphoid neoplasms. 2017 , 54, 99-109	18
1441	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. 2017 , 5, 312-318	259
1440	Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities. 2017 , 22, 304-310	6
1439	The squamous situation: Ancillary testing in pulmonary squamous cell carcinoma and implications for cytology laboratories. 2017 , 125, 153-154	
1438	Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis. 2017 , 43, 1372-1379	22
1437	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. 2017 , 18, e143-e152	1010
1436	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version). 2017 , 13, 87-103	29
1435	Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. 2017 , 106, 70-75	26
1434	PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. 2017 , 6, e1284722	58
1433	Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer. 2017 , 66, 215-225	28
1432	Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation. 2017 , 15, 5	23
1431	LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. 2017 , 12, 814-823	122
1430	High expression of PD-1 ligands is associated with mutational signature and APOBEC3 alterations. 2017 , 6, e1284719	42
1429	A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. 2017 , 54, 58-67	231
1428	Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. 2017 , 45, 160-169	220
1427	Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice. 2017 , 19, 5	

1426	Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence. 2017 , 34, 34	20
1425	Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. 2017 , 10, 64	20
1424	Checkpoint Blockade in Lung Cancer and Mesothelioma. 2017 , 196, 274-282	42
1423	Emerging challenges of advanced squamous cell lung cancer. 2016 , 1, e000129	4
1422	Biological therapies in nonsmall cell lung cancer. 2017 , 49,	29
1421	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. 2017 , 13, 1159-1171	12
1420	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. 2017 , 14, 1049-1065	15
1419	Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. 2017 , 6, e1269047	35
1418	Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. 2017 , 35, 142-148	12
1417	HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. 2017 , 6, e1293214	19
1416	Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data. 2017 , 141, 1018-1028	79
1415	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. 2017 , 18, 572-582.e1	39
1414	The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. 2017 , 111, 124-132	67
1413	The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. 2017 , 37, 1545-1554	80
1412	Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study. 2017 , 13, 137-144	2
1411	Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. 2017 , 44, 3-7	63
1410	Traditional Oriental Herbal Medicine and Natural Killer Cells for Cancer Patients: A Systematic Review and Meta-analysis. 2017 , 31, 519-532	9
1409	Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab. 2017 , 8, 175-180	4

1408	Layered double hydroxide bio-composites toward excellent systematic anticancer therapy. 2017 , 5, 3212-3216	18
1407	End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. 2017 , 13, 1181-1193	19
1406	Pembrolizumab in recurrent advanced cervical squamous carcinoma. 2017 , 9, 467-470	10
1405	Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. 2017 , 62, 205-213	8
1404	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. 2017 , 78, 16-23	75
1403	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. 2017 , 389, 2492-2502	2151
1402	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. 2017 , 129, 3419-3427	244
1401	Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. 2017 , 141, 851-861	64
1400	Small cell lung cancer transformation during immunotherapy with nivolumab: A case report. 2017 , 21, 52-55	18
1399	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. 2017 , 22, 690-697	17
1398	Repolarizing macrophages improves breast cancer therapy. 2017 , 27, 963-964	26
1397	Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. 2017 , 24, 2698-2706	20
1396	Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab. 2017 , 93, 62-66	10
1395	Nivolumab induced myxedema crisis. 2017 , 5, 13	34
1394	Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. 2017 , 22, 700-708	9
1393	WITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. 2017 ,	
1392	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. 2017 , 109, 1-8	19
1391	Immune checkpoint inhibitors in lung cancer: an update. 2017 , 13, 955-959	4

1390	Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. 2017 , 152, 271-281	249
1389	Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. 2017 , 10, 105	67
1388	How tumor growth can be influenced by delayed interactions between cancer cells and the microenvironment?. 2017 , 158, 17-30	48
1387	Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs. 2017 , 18, e363-e365	10
1386	Epigenetics and immunotherapy: The current state of play. 2017 , 87, 227-239	128
1385	[Cancer, radiotherapy and immune system]. 2017 , 21, 307-315	8
1384	Emerging therapies for breast cancer. 2017 , 10, 98	37
1383	Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. 2017 , 18, 682-691.e5	57
1382	Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. 2017 , 12, 1085-1097	128
1381	PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. 2017 , 9, 499-506	122
1380	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. 2017 , 9, 507-520	8
1379	A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. 2017 , 13, 1765-1767	2
1378	Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors. 2017 , 64, e26613	33
1377	Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the Lung. 2017 , 12, e135-e136	32
1376	RECISTing the Temptation to Prematurely Stop Nivolumab. 2017 , 72, 377-378	
1375	AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. 2017 , 195, 1150-1160	57
1374	Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. 2017 , 28, 1996-2001	150
1373	Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. 2017 , 11, 469-479	9

1372	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. 2017 , 133, 331-338	77
1371	Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor. 2017 , 15, e855-e857	18
1370	Pancreatic Cancer. 2017 ,	1
1369	Immune Biomarkers on the Radar-Comprehensive "Immunograms" for Multimodal Treatment Prediction. 2017 , 12, 770-772	1
1368	Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. 2017 , 108, 1000-1006	49
1367	Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis. 2017 , 16, 1588-1595	16
1366	The Immunobiology of Cancer: From Tumor Escape to Cancer Immunoediting Towards Immunotherapy in Gynecologic Oncology. 2017 , 193-204	1
1365	Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. 2017 , 26, 1139-1145	52
1364	KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. 2017 , 66, 1175-1187	140
1363	The next generation of immunotherapy: keeping lung cancer in check. 2017 , 10, 87	63
1362	Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?. 2017 , 13, 381-383	3
1361	Immunotherapy in Lung Cancer. 2017 , 31, 131-141	26
1360	Systemic Treatment of Brain Metastases. 2017 , 31, 157-176	6
1359	The safety of nivolumab for the treatment of advanced non-small cell lung cancer. 2017 , 16, 101-109	6
1358	New Targets in Non-Small Cell Lung Cancer. 2017 , 31, 113-129	16
1357	Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. 2017 , 31, 31-44	6
1356	Raising the bar on first-line immunotherapy in lung cancer. 2017 , 18, 2-3	3
1355	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. 2017 , 18, 31-41	605

1354	PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. 2017 , 12, 208-222	812
1353	Real-world data on nivolumab treatment of non-small cell lung cancer. 2017 , 56, 438-440	36
1352	The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. 2017 , 93, 1-14	6
1351	Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab. 2017 , 28, 2040-2041	19
1350	Relationship of the Breast Ductal Carcinoma Immune Microenvironment with Clinicopathological and Genetic Features. 2017 , 23, 5210-5217	41
1349	Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. 2017 , 3, e171029	46
1348	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. 2017 , 143, 1977-1984	11
1347	Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?. 2017 , 125, 591-593	3
1346	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. 2017 , 11, 317-370	955
1345	Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung. 2017 , 6, 131-134	2
1344	PD-L1 Expression in Pancreatic Cancer. 2017 , 109,	26
1343	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. 2017 , 12, 563-569	50
1342	Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. 2017 , 38, 223-232	23
1341	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. 2017 , 57, 36-49	185
1340	Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. 2017 , 4, 169-173	25
1339	Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. 2017 , 28, 2002-2008	108
1338	Immune Signatures of Non-Small Cell Lung Cancer. 2017 , 12, 913-915	4
1337	Immunogenomics: using genomics to personalize cancer immunotherapy. 2017 , 471, 209-219	5

1336	Immune Checkpoint Blockade and Gastric Cancer. 2017 , 115-130		2
1335	Advancing Immunotherapy in Metastatic Breast Cancer. 2017 , 18, 35		12
1334	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. 2017 , 102, 2770-2780		125
1333	Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. 2017 , 22, 737-742		56
1332	Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients. <i>New England Journal of Medicine</i> , 2017 , 376, 2483-2485	59.2	22
1331	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017 , 376, 2415-2426	59.2	1474
1330	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. 2017 , 6, e1339856		6
1329	The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. 2017 , 28, 2256-2263		54
1328	Aloe-emodin (AE) nanoparticles suppresses proliferation and induces apoptosis in human lung squamous carcinoma via ROS generation in vitro and in vivo. 2017 , 490, 601-607		30
1327	Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. 2017 , 58, 70-76		173
1326	PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. 2017 , 28, 882-889		77
1325	CD45RAFoxp3 regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma. 2017 , 66, 1275-1285		29
1324	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. 2017 , 12, 301-308		47
1323	Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. 2017 , 38, 577-593		190
1322	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. 2017 , 18, 33		9
1321	A case of cystitis after administration of nivolumab. 2017 , 6, 164-166		9
1320	Programmed cell death-1/Programmed cell death ligand-1(PD-1/PD-L1) inhibitors, heralding a new era of immunotherapy in the management of advanced Non-Small Cell Lung Cancer (NSCLC). 2017 , 12, 6-13		8
1319	Checkpoint inhibitors for the treatment of non-small-cell lung cancer: news from the 2016 European Society for Medical Oncology Annual Congress. 2017 , 33, 126-132		1

1318	DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. 2017 , 110, 26-31	44
1317	Clinical applications of PD-L1 bioassays for cancer immunotherapy. 2017 , 10, 110	51
1316	Combining radiotherapy with immunotherapy: the past, the present and the future. 2017 , 90, 20170157	60
1315	Immunotherapy for lung cancer: Targeting the PD-1 pathway. 2017 , 30, 48-50	
1314	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, -glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. 2017 , 16, 1705-1717	36
1313	Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review. 2017 , 17, 725-736	15
1312	An Introduction to Immunotherapy in the Treatment of Brain Tumors. 2017 , 1-10	
1311	Checkpoint Blockade Immunotherapy for Glioblastoma. 2017 , 261-300	2
1310	The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. 2017 , 35, 30-39	79
1309	Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. 2017 , 99, 153-164	52
1308	Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody. 2017 , 109, 74-77	13
1307	Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials. 2017 , 49, 85-94	21
1306	Evaluation of the VeriStrat serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. 2017 , 109, 101-108	24
1305	Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. 2017 , 108, 1022-1031	66
1304	High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. 2017 , 3,	16
1303	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. 2017 , 34, 121	11
1302	Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. 2017 , 18, 887-894	76
1301	Gastric adenocarcinoma. 2017 , 3, 17036	251

1300	Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer. 2017 , 35, 848-850	9
1299	Understanding the checkpoint blockade in lung cancer immunotherapy. 2017 , 22, 1266-1273	36
1298	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. 2017 , 9, 579-587	10
1297	Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. 2017 , 123, 3807-3815	99
1296	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. 2017 , 28, 1988-1995	210
1295	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. 2017 , 22, 627-630	49
1294	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. 2017 , 17, 647-655	10
1293	Addressing the quality of the ESMO-MCBS. 2017 , 28, 1406	8
1292	Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. 2017 , 23, 6002-6011	21
1291	Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. 2017 , 9, 431-439	51
1290	New insights into the role of EMT in tumor immune escape. 2017 , 11, 824-846	180
1289	Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types. 2017 , 18, 556-557	18
1288	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. 2017 , 18, 599-610	215
1287	Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. 2017 , 103, 1750-1757	22
1286	Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape. 2017 , 9, 375-378	2
1285	Drug-biomarker co-development in oncology - 20 years and counting. 2017 , 30, 48-62	38
1284	Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. 2017 , 31, 1048-1051	61
1283	Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment. 2017 , 8, 275-277	12

1282	Milestones in the systemic treatment of lung cancer. 2017 , 10, 22-26	6
1281	Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1. 2017 , 18, 673-684	30
1280	Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. 2017 , 18, 559-564	8
1279	Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment. 2017 , 108, 7-8	6
1278	Case report of nivolumab-related pneumonitis. 2017 , 9, 313-318	5
1277	Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. 2017 , 995, 97-125	69
1276	Computed Tomography Features of Lung Adenocarcinomas With Programmed Death Ligand 1 Expression. 2017 , 18, e375-e383	15
1275	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. 2017 , 46, 210-219	71
1274	Mechanistic and pharmacologic insights on immune checkpoint inhibitors. 2017 , 120, 1-9	29
1273	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. 2017 , 15, 55	43
1272	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. 2017 , 3, 974-978	49
1271	Overview of Basic Immunology for Clinical Investigators. 2017 , 995, 1-31	4
1270	Development of CAR T cells designed to improve antitumor efficacy and safety. 2017 , 178, 83-91	67
1269	Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. 2017 , 7, 45124	49
1268	Liquid Biopsies in Solid Tumors. 2017 ,	
1267	PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. 2017 , 66, 865-876	94
1266	Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer). 2017 ,	3
1265	Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?. 2017 , 108, 90-95	5

1264	PD-L1 expression in neuroendocrine tumors of the lung. 2017 , 108, 115-120	81
1263	Prospects and progress of atezolizumab in non-small cell lung cancer. 2017 , 17, 781-789	11
1262	Pembrolizumab for the treatment of non-small cell lung cancer. 2017 , 17, 399-409	24
1261	How many tumor indications should be initially screened in development of next generation immunotherapies?. 2017 , 59, 113-117	12
1260	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. 2017 , 19, 1058-1067	27
1259	Strategies for Increasing Pancreatic Tumor Immunogenicity. 2017 , 23, 1656-1669	92
1258	Cancer immunotherapies targeting the PD-1 signaling pathway. 2017 , 24, 26	332
1257	Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient. 2017 , 28, 1405-1406	8
1256	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. 2017 , 44, 67-77	84
1255	Nivolumab induced radiation recall pneumonitis after two years of radiotherapy. 2017 , 28, 1404-1405	68
1254	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. 2017 , 34, 331-357	6
1253	Stereotactic Ablative Radiotherapy Induces Peripheral T-Cell Activation in Patients with Early-Stage Lung Cancer. 2017 , 196, 1224-1227	7
1252	Detecting and Monitoring Circulating Stromal Cells from Solid Tumors Using Blood-Based Biopsies in the Twenty-First Century: Have Circulating Stromal Cells Come of Age?. 2017 , 81-104	2
1251	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. 2017 , 31, 476-485	86
1250	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. 2017 , 16, 573-585	16
1249	Immunotherapy for gastric cancers: emerging role and future perspectives. 2017 , 10, 609-619	26
1248	Comorbidities in the management of patients with lung cancer. 2017 , 49,	42
1247	Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. 2017 , 13, 1263-1279	77

1246	Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas. 2017 , 9, 411-421	2
1245	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. 2017 , 20, 185-204	309
1244	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. 2017 , 18, 587-598	194
1243	Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. 2017 , 9, 423-433	6
1242	The Microenvironmental Landscape of Brain Tumors. 2017 , 31, 326-341	688
1241	A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis. 2017 , 7, 694-703	95
1240	Urethral Cancer. 2017 , 54-67	
1239	Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. 2017 , 18, 631-639	247
1238	Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient. 2017 , 108, 72-74	21
1237	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. 2017 , 5, 8	86
1236	[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma]. 2017 , 58, 409-423	1
1235	Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. 2017 , 18, 595-606	34
1234	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. 2017 , 178, 31-47	58
1233	Biomarkers and Immunotherapeutic Targets in Glioblastoma. 2017 , 102, 494-506	19
1232	Novel agents in classical Hodgkin lymphoma. 2017 , 58, 2275-2286	12
1231	Metastatic clival chordoma: a case report of multiple extraneural metastases following resection and proton beam radiotherapy in a 5-year old boy. 2017 , 19, 531-537	1
1230	Immunotherapy. 2017 ,	4
1229	PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8 tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining. 2017 , 22, 726-733	38

1228	Radiation and Immune Checkpoint Blockade: From Bench to Clinic. 2017 , 27, 289-298	28
1227	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. 2017 , 5, 12	121
1226	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. 2017 , 35, 529-536	90
1225	Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. 2017 , 12, 943-953	88
1224	Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. 2017 , 5, 29-41	190
1223	T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. 2017 , 140, 2535-2544	30
1222	Current progress in immunotherapy of hepatocellular carcinoma. 2017 , 66, 482-484	36
1221	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. 2017 , 28, 583-589	348
1220	Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. 2017 , 28, 671-672	59
1219	Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. 2017 , 9, 5-8	18
1218	Immuno-Oncology: The Third Paradigm in Early Drug Development. 2017 , 12, 125-138	16
1217	Targeted Therapies for Ovarian Cancer. 2017 , 41, 139-152	53
1216	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. 2017 , 12, 752-762	13
1215	Atypical autoimmune adverse effects with checkpoint blockade therapies. 2017 , 28, 206-207	11
1214	Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma. 2017 , 6, 40-48	53
1213	Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. 2017 , 19, i1-i24	122
1212	Molecular approaches for classifying endometrial carcinoma. 2017 , 145, 200-207	88
1211	Advances in the molecular genetics of gliomas - implications for classification and therapy. 2017 , 14, 434-452	320

1210	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. 2017 , 7, 264-276	491
1209	Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. 2017 , 18, 1-4	6
1208	Current Trends in Cancer Therapy. 2017 , 1-24	3
1207	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). 2017 , 18, 333-339	32
1206	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. 2017 , 6, e1260214	5
1205	Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity. 2017 , 110, 1-12	50
1204	Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma. 2017 , 11, 129-132	1
1203	Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. 2017 , 9, 46-58	26
1202	Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. 2017 , 29, 218-230	37
1201	Association of Cytoplasmic CXCR4 With Loss of Epithelial Marker and Activation of ERK1/2 and AKT Signaling Pathways in Non-Small-Cell Lung Cancer. 2017 , 18, e203-e210	11
1200	Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. 2017 , 41, 111-124	30
1199	Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. 2017 , 35, 243-252	15
1198	Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. 2016 , 6, 1-12	42
1197	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. 2017 , 49, 141-155	68
1196	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. 2017 , 76, 43-50	248
1195	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. 2017 , 35, 785-792	696
1194	Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. 2017 , 69, 1751-1763	216
1193	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. 2017 , 389, 255-265	2681

1192	Programmed death of chemotherapy in non-small-cell lung cancer?. 2017 , 389, 227-228	4
1191	Emerging biomarkers for PD-1 pathway cancer therapy. 2017 , 11, 53-67	9
1190	The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. 2017 , 104, 7-15	54
1189	Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer. 2017 , 77, 851-861	35
1188	Clinical trials of CAR-T cells in China. 2017 , 10, 166	54
1187	Chemotherapy enhances programmed cell death '1/ligand'1 expression via TGF- β -induced epithelial mesenchymal transition in non-small cell lung cancer. 2017 , 38, 2277-2284	22
1186	Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). 2017 , 9, 1309-1321	35
1185	[Personalized therapy of lung cancer - current standard and future challenges]. 2017 , 142, 1660-1668	0
1184	Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer. 2017 , 80, 1189-1196	5
1183	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. 2017 , 16, 301-308	4
1182	S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?. 2017 , 28, 2627-2629	0
1181	Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. 2017 , 12, 1798-1805	241
1180	PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung. 2017 , 51, 357-362	28
1179	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. 2017 , 2, e000236	19
1178	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. 2017 , 9, 995-1004	10
1177	The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma. 2017 , 23, 7633-7640	13
1176	Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on F-fluorodeoxyglucose positron emission tomography/computed tomography. 2017 , 6, 2552-2561	58
1175	A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis. 2017 , 24, 1073274817729069	17

1174	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 2017 , 15, 1240-1267	172
1173	c-Jun N-terminal kinase in pancreatic tumor stroma augments tumor development in mice. 2017 , 108, 2156-2165	12
1172	PD-L1 IHC in NSCLC with a global and methodological perspective. 2017 , 113, 102-105	25
1171	Biomarker Panels and Contemporary Practice in Clinical Trials of Targeted Therapy. 2017 , 507-523	
1170	4-1BB Agonist Focuses CD8 Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. 2017 , 23, 7263-7275	29
1169	Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. 2017 , 23, 7474-7482	40
1168	Cutting the Brakes: Immunotherapy With PD-1 Inhibitors. 2017 , 2, 24-31	2
1167	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. 2017 , 119, 30-39	29
1166	Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. 2017 , 86, 15-27	44
1165	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. 2017 , 7, 1420-1435	302
1164	PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. 2017 , 125, 896-907	119
1163	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. 2017 , 171, 934-949.e16	831
1162	Extracellular nucleosides and nucleotides as immunomodulators. 2017 , 280, 83-92	64
1161	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. 2017 , 15, 205	13
1160	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 2017 , 17, 1055-1069	19
1159	PD-L1 expression in HNPCC-associated colorectal cancer. 2017 , 213, 1552-1555	6
1158	[Lung cancer : What has been confirmed in therapy?]. 2017 , 58, 1258-1263	1
1157	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. 2017 , 8, 1050	75

1156	A conduit to metastasis: circulating tumor cell biology. 2017 , 31, 1827-1840	205
1155	Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice. 2017 , 62, 374-380	9
1154	Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. 2017 , 3, 360-373	7
1153	Mechanisms regulating T-cell infiltration and activity in solid tumors. 2017 , 28, xii18-xii32	175
1152	Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead. 2017 , 28, 2923-2931	28
1151	Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab. 2017 , 9, 955-961	21
1150	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. 2017 , 86, 257-265	21
1149	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. 2017 , 28, 2860-2865	71
1148	Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?. 2017 , 28, 2950-2961	56
1147	Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer. 2017 , 21, 211-220	2
1146	Cancer: Towards a general theory of the target: All successful cancer therapies, actual or potential, are reducible to either (or both) of two fundamental strategies. 2017 , 39, 1700059	2
1145	Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. 2017 , 38, 1877-1885	18
1144	Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors. 2017 , 104, e217-e218	40
1143	Immunotherapy for Non-Small Cell Lung Cancer: A Therapy for All Stages?. 2017 , 29, 416-417	
1142	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). 2017 , 84, 212-218	78
1141	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. 2017 , 18, 1477-1490	16
1140	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. 2017 , 11, 353-373	19
1139	Nivolumab-associated nausea and vomiting as an immune adverse event. 2017 , 84, 367-369	7

1138	Radiotherapy in combination with immune checkpoint inhibitors. 2017 , 29, 105-111	12
1137	Severe acute interstitial lung disease after nivolumab in three non-small cell lung cancer patients with imaging findings of airway obstruction adjacent to lung tumors. 2017 , 23, 826-829	11
1136	Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?. 2017 , 27, 566-571	9
1135	New Immunotherapy and Lung Cancer. 2017 , 53, 682-687	6
1134	Lung Cancer in the Older Patient. 2017 , 33, 563-577	13
1133	Antigen-Presenting Intratumoral B Cells Affect CD4 TIL Phenotypes in Non-Small Cell Lung Cancer Patients. 2017 , 5, 898-907	102
1132	CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy. 2017 , 13, 2272-2279	
1131	PDL-1/PD1 inhibitors: antibody or antinobody?. 2017 , 13, 1669-1671	7
1130	Bevacizumab in advanced lung cancer: state of the art. 2017 , 13, 2515-2535	33
1129	Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. 2017 , 6, 169-174	10
1128	Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017 , 377, 849-861	59.2 376
1127	Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers. 2017 , 9, 767-780	8
1126	Prognostic value of tumor PD-L1 expression combined with CD8 tumor infiltrating lymphocytes in high grade serous ovarian cancer. 2017 , 52, 7-14	49
1125	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. 2017 , 117, 913-920	111
1124	ATS Core Curriculum 2017: Part IV. Adult Pulmonary Medicine. 2017 , 14, S196-S208	
1123	The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. 2017 , 12, 709-718	13
1122	Tumour radiosensitivity is associated with immune activation in solid tumours. 2017 , 84, 304-314	27
1121	Trial watch: Immune checkpoint blockers for cancer therapy. 2017 , 6, e1373237	53

1120	A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002). 2017 , 80, 955-963	10
1119	Who treats lung cancer? Results from a global survey. 2017 , 55, 308-313	3
1118	Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer. 2017 , 23, 5394-5405	48
1117	Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. 2017 , 9, 913-927	24
1116	Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. 2017 , 85, 155-157	5
1115	Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. 2017 , 57 Suppl 10, S26-S42	63
1114	Nucleobase-modified polyamidoamine-mediated miR-23b delivery to inhibit the proliferation and migration of lung cancer. 2017 , 5, 2268-2275	19
1113	Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. 2017 , 410, 3-27	36
1112	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. 2017 , 60, 60-68	83
1111	PD-1 checkpoint inhibition: Toxicities and management. 2017 , 35, 701-707	44
1110	Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. 2017 , 7, 11373	42
1109	PD-1 Status in CD8 T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. 2017 , 77, 6353-6364	111
1108	Role of PD-1 in Immunity and Diseases. 2017 , 410, 75-97	85
1107	PD-L1 is an activation-independent marker of brown adipocytes. 2017 , 8, 647	65
1106	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. 2017 , 50, 185-194	21
1105	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. 2017 , 35, 1195-1209	14
1104	Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors. 2017 , 12, 1626-1635	55
1103	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. 2017 , 23, 4959-4969	71

1102	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. 2017 , 73, 138-146	61
1101	CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients. 2017 , 7, e601	8
1100	An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma. 2017 , 22, 213-222	5
1099	PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. 2017 , 7, 10255	110
1098	Neurological Complications of Immunotherapies-Beware of the Checkpoint Ahead. 2017 , 74, 1176-1177	1
1097	Case series of pleomorphic carcinomas of the lung treated with nivolumab. 2017 , 8, 724-728	35
1096	Atezolizumab for the treatment of non-small cell lung cancer. 2017 , 10, 935-945	21
1095	[Immunotherapy: Activation of a system not a pathway]. 2017 , 104, 462-475	
1094	Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. 2017 , 6, e1338997	22
1093	Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer. 2017 , 111, 182-189	20
1092	Cancer Immunotherapy in Older Patients. 2017 , 23, 219-222	14
1091	The Biology of Aging and Cancer: Frailty, Inflammation, and Immunity. 2017 , 23, 201-205	43
1090	Lung cancer as a paradigm for precision oncology in solid tumours. 2017 , 471, 221-233	10
1089	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. 2017 , 59, 71-78	65
1088	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. 2017 , 80, 591-598	34
1087	Immunotherapy targeting immune check-point(s) in brain metastases. 2017 , 36, 33-38	7
1086	Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. 2017 , 14, 1568-1580	8
1085	Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India. 2017 , 31, 56-61	12

1084	Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. 2017 , 13, 277-288	31
1083	PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. 2017 , 152, 357-371	85
1082	[Percutaneous lung thermo-ablation]. 2017 , 104, 417-422	3
1081	C�ncer de pulm�n no microc�lico. 2017 , 12, 1811-1824	
1080	Adenocarcinoma de pulm�n diseminado de dif�cil manejo. 2017 , 12, 1887.e1-1887.e3	
1079	[Current knowledge on perioperative treatments of non-small cell lung carcinomas]. 2017 , 34, 618-634	5
1078	Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. 2017 , 44, 132-135	64
1077	Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report. 2017 , 96, e7350	35
1076	Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. 2017 , 108, 1223-1230	47
1075	CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. 2017 , 66, 1449-1461	38
1074	Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. 2017 , 17, 834-851	32
1073	Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. 2017 , 83, 28-31	27
1072	Chimioth�rapies personnalis�es du cancer bronchique : ce que le radiologue doit conna�tre. 2017 , 98, 146-156	
1071	Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade. 2017 , 141, 1891-1900	20
1070	Supportive care for patients undergoing immunotherapy. 2017 , 25, 3017-3030	39
1069	Cancer Immunotherapies: Are They as Effective in the Elderly?. 2017 , 34, 567-581	22
1068	Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. 2017 , 111, 6-11	2
1067	The "value" of immune-checkpoint inhibitors for advanced lung cancer. 2017 , 55, 253-254	

1066	A Case of Heart Failure after Treatment with Anti-PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient. 2017 , 12, e128-e130	5
1065	Immunotherapy: Who Is Eligible?. 2017 , 50, 867-874	4
1064	Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. 2017 , 30, 1622-1632	41
1063	Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma. 2017 , 13, 385-390	24
1062	Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment. 2017 , 50,	12
1061	Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. 2017 , 19, 62	11
1060	Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. 2017 , 111, 176-181	370
1059	Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. 2017 , 28, 186-189	13
1058	Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice. 2017 , 125, 521-528	7
1057	Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation. 2017 , 58, 446-455	32
1056	Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab. 2017 , 2, e000145	9
1055	Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer. 2017 , 28, 2078-2089	11
1054	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge. 2017 , 83, 266-278	16
1053	Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-Small Cell Lung Cancer. 2017 , 12, 1733-1736	2
1052	Precision regimen for personalized pancreatic cancer therapy. 2017 , 1, 44-45	
1051	Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer. 2017 , 12, 1536-1543	41
1050	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. 2017 , 2, e000200	25
1049	Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. 2017 , 29, 97-104	29

1048	Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report. 2017 , 96, e5951	14
1047	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. 2017 , 38, 489-515	151
1046	The importance for immunoregulation for long-term cancer control. 2017 , 13, 1619-1632	8
1045	Lung cancer as a cardiotoxic state: a review. 2017 , 34, 159	7
1044	Immunotherapy in Non-Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging. 2017 , 32, 300-312	35
1043	Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. 2017 , 2, e000102	7
1042	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. 2017 , 44, 2310-2325	34
1041	Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report. 2017 , 7, 383-385	13
1040	The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. 2017 , 5, 767-777	69
1039	Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. 2017 , 176, 1163-1172	9
1038	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. 2017 , 17, 75	13
1037	Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives. 2017 , 59, 109-116	83
1036	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. 2017 , 50,	192
1035	[Clinical pharmacology and immunotherapy, 4th edition of the congress of pharmacology of anticancer drugs]. 2017 , 104, 807-811	0
1034	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. 2017 , 112, 90-95	128
1033	PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. 2017 , 112, 200-215	122
1032	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. 2017 , 19, 64	71
1031	Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma. 2017 , 57, 1527-1533	22

1030	EGFR tyrosine kinase inhibitors chemotherapy in wild-type pre-treated advanced nonsmall cell lung cancer in 'daily practice. 2017 , 50,	12
1029	MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. 2017 , 6, e1338998	28
1028	Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. 2017 , 6, e1346764	37
1027	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma	299
1026	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. 2017 , 24, 235-251	293
1025	Hypothyroid ataxia complicating monoclonal antibody therapy. 2017 , 17, 482-484	3
1024	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. 2017 , 18, 51	56
1023	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. 2017 , 28, 2377-2385	372
1022	Oncogenic RAS Signaling Promotes Tumor Immuno-resistance by Stabilizing PD-L1 mRNA. 2017 , 47, 1083-1099. 61	61
1021	Checkpoint inhibition in pediatric hematologic malignancies. 2017 , 34, 379-394	16
1020	[Current Aspects of Diagnosis and Treatment of Lung Cancer]. 2017 , 142, 1808-1812	3
1019	New Immunotherapy and Lung Cancer. 2017 , 53, 682-687	3
1018	DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. 2017 , 8, 1751	300
1017	Quality matters: immunotherapy and the evolving landscape of advanced cancer care. 2017 , 2, 235-244	2
1016	Targeting immune checkpoints in breast cancer: an update of early results. 2017 , 2, e000255	79
1015	Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue. 2017 , 12, 1177271917699850	2
1014	De-novo and acquired resistance to immune checkpoint targeting. 2017 , 18, e731-e741	383
1013	Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy. 2017 , 17, 7387-7393	139

1012	Personalised medicine for nonsmall cell lung cancer. 2017 , 26,	28
1011	Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?. 2017 , 22, 1470-1477	7
1010	Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis. 2017 , 2, e000119	6
1009	Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017 , 377, 1986-1988	59.2 31
1008	[Autoimmune reactions to immune checkpoint inhibitors]. 2017 , 76, 57-62	1
1007	Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. 2017 , 86, 349-357	59
1006	Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression. 2017 , 3, 268-278	13
1005	What's new in chemotherapy for non-small cell lung cancer?. 2017 , 10, 123-126	
1004	Cardiotoxicity of immune checkpoint inhibitors. 2017 , 2, e000247	126
1003	Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells. 2017 , 12, 2006-2013	6
1002	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. 2017 , 18, 1600-1609	185
1001	Adherence to surveillance guidelines in resected NSCLC: Physician compliance and impact on outcomes. 2017 , 112, 176-180	1
1000	Changing costs of metastatic non small cell lung cancer in the Netherlands. 2017 , 114, 56-61	7
999	Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis. 2017 , 96, e8407	8
998	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. 2017 , 18, 1104-1115	232
997	Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. 2017 , 403, 159-164	32
996	An abscopal effect in a case of concomitant treatment of locally and peritoneally recurrent gastric cancer using adoptive T-cell immunotherapy and radiotherapy. 2017 , 5, 380-384	19
995	Checkpointinhibitoren. 2017 , 23, 619-625	

994	Overall survival and prognostic factors in patients with spinal metastases from lung cancer treated with and without epidermal growth factor receptor tyrosine kinase inhibitors. 2017 , 22, 698-705	7
993	Immune checkpoint inhibitors and elderly people: A review. 2017 , 82, 155-166	99
992	Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre. 2017 , 28, 654-659	2
991	Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. 2017 , 111, 65-68	13
990	Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. 2017 , 13, 1893-1905	8
989	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. 2017 , 12, 475-485	23
988	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2017 , 28, iv119-iv142	1100
987	Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples. 2017 , 18, e473-e479	27
986	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. 2017 , 405, 29-37	51
985	Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases. 2017 , 81, 138-141	0
984	Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class 1-related chain A and B in cancer cells. 2017 , 38, 693-702	14
983	Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. 2017 , 23, 5948-5958	66
982	PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. 2017 , 66, 13-33	34
981	Biomarkers of response to PD-1/PD-L1 inhibition. 2017 , 116, 116-124	185
980	Avancès mēdicamenteuses en oncologie thoracique. 2017 , 26, 257	
979	Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions. 2017 , 5, 69-74	4
978	Continued Response to One Dose of Nivolumab Complicated by Myasthenic Crisis and Myositis. 2017 , 12, e90-e91	31
977	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. 2017 , 14, 655-668	498

976	Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. 2017 , 28, 2893-2895	39
975	Optimale Therapie des nichtkleinzelligen Lungenkarzinoms im Stadium IIIB/C. 2017 , 20, 32-42	
974	Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. 2017 , 18, 120	25
973	Precision medicine in breast cancer: reality or utopia?. 2017 , 15, 139	38
972	Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. 2017 , 11, 73	39
971	Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. 2017 , 5, 31	35
970	Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. 2017 , 5, 40	74
969	Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. 2017 , 5, 46	49
968	The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. 2017 , 9, 681-692	69
967	Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review. 2017 , 9, 701-707	15
966	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. 2017 , 3, 1511-1519	101
965	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. 2017 , 36, 5-15	33
964	A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. 2017 , 111, 1-5	43
963	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. 2017 , 124, 98-103	43
962	PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. 2017 , 30, 1411-1421	114
961	Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations. 2017 , 209, 567-575	22
960	Immunotherapeutic Approaches to Biliary Cancer. 2017 , 18, 44	8
959	Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer. 2017 , 96, e7346	15

958	Nivolumab-Induced Granulomatous Inflammation of the Pleura. 2017 , 12, e100-e101	5
957	Immunecheckpointinhibitoren. 2017 , 23, 575-584	
956	Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study. 2017 , 23, 733-739	11
955	PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. 2017 , 14, 203-220	250
954	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. 2017 , 23, 1920-1928	698
953	EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. 2017 , 385, 51-54	128
952	The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. 2017 , 29, 153-160	39
951	Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. 2017 , 12, 281-292	66
950	Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. 2017 , 30, 340-349	105
949	Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. 2017 , 17, 47-59	27
948	Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. 2017 , 28, 34-43	146
947	Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. 2017 , 105, 383-386	49
946	Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. 2017 , 119, 579-584	12
945	Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. 2017 , 23, 342-350	34
944	New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?. 2017 , 18, 35-44	16
943	Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. 2017 , 38, 25-40	62
942	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. 2017 , 44, 158-176	135
941	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. 2017 , 28, 57-74	32

940	Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. 2017 , 30, 278-285	59
939	Cytological reporting on lung FNA and small biopsy specimens in the era of personalized medicine. 2017 , 125, 155-160	1
938	Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials. 2017 , 140, 948-958	33
937	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. 2017 , 66, 45-50	44
936	Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?. 2017 , 13, 528-532	23
935	Antibody therapeutics for treating prostate cancer: where are we now and what comes next?. 2017 , 17, 135-149	4
934	Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer. 2017 , 18, 132-140	15
933	Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation. 2017 , 58, 754-755	10
932	Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. 2017 , 44, 117-122	121
931	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. 2017 , 22, 81-88	95
930	Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors. 2017 , 57, 394-400	38
929	Lung cancer: current therapies and new targeted treatments. 2017 , 389, 299-311	1358
928	CD137-CRDI is not necessary in the role of contacting its natural ligand. 2017 , 95, 24-32	3
927	PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus. 2017 , 60, 16-23	35
926	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. 2017 , 12, 194-207	132
925	OMIP-037: 16-color panel to measure inhibitory receptor signatures from multiple human immune cell subsets. 2017 , 91, 175-179	11
924	Management of Adrenal Masses in Children and Adults. 2017 ,	4
923	Global chemotherapy development for gastric cancer. 2017 , 20, 92-101	24

922	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. 2017 , 77, 123-144	4
921	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. 2017 , 28, 368-376	468
920	Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. 2017 , 80, 7-14	28
919	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. 2017 , 14, 15-25	138
918	Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. 2017 , 18, 100-103	7
917	Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach. 2017 , 18, 220-233.e8	60
916	Immunotherapy Comes of Age in Lung Cancer. 2017 , 18, 13-22	49
915	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. 2017 , 23, 370-378	101
914	W'ALK' Into the Next Stage. 2017 , 18, 122-126	5
913	Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. 2017 , 62, 397-405	31
912	Ultrasonographic findings can identify 'pseudoprogression' under nivolumab therapy. 2017 , 177, 1726-1731	9
911	Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer. 2017 , 56, 441-447	22
910	Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. 2017 , 10, 31-38	16
909	Immunotherapy approaches in the treatment of malignant brain tumors. 2017 , 123, 734-750	63
908	Next generation predictive biomarkers for immune checkpoint inhibition. 2017 , 36, 179-190	67
907	CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. 2017 , 6, e1249558	52
906	The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. 2017 , 103, 27-37	89
905	A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. 2017 , 28, 285-291	10

904	Penile Cancer. 2017,	
903	Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. 2017, 43, 65-78	78
902	Metastatic Anal Cancer and Novel Agents. 2017, 26, 133-142	6
901	The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer. 2017, 68, 153-168	20
900	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. 2017, 12, 110-120	76
899	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. 2017, 35, 709-717	587
898	Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion. 2017, 136, 49-51	54
897	Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. 2017, 24, 135-141	22
896	Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. 2017, 22, 70-80	41
895	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. 2017, 109,	104
894	Hepatocellular Carcinoma. 2017, 977-988	
893	Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer. 2017, 96, e9320	7
892	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials. 2017, 96, e8931	17
891	Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. 2017,	78
890	Traitement de première ligne et de maintenance dans les CBNPC avancés en l'absence d'addiction oncologique. 2017, 9, 234-247	
889	Cancer bronchique non ^ petites cellules de stade IV sans addiction oncologique : traitements en 2 e ligne et au-del^ . 2017, 9, 248-258	
888	Méastases cérébrales des cancers bronchiques non ^ petites cellules (CBNPC). 2017, 9, 271-287	
887	Immunothérapie et cancer du poumon : en sommes-nous ? 2017, 9, 315-324	0

886	Les complications de lâimmunoth�apie. 2017 , 9, 325-331	1
885	Toxicit�pulmonaire de lâimmunoth�apie par les inhibiteurs de point de contr�le. 2017 , 9, 469-474	1
884	Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. 2017 , 28, 3106-3107	12
883	Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy. 2017 , 9, 769-779	9
882	EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. 2017 , 28, iv84-iv99	157
881	Outcomes after surgical resection of thymic carcinoma. 2017 , 31, 148-154	
880	Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. 2017 , 6, 93-107	3
879	"Lazarus response" of nivolumab in a frail patient with non-small-cell lung cancer. 2017 , 5, e00247	4
878	Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. 2017 , 36, 94	35
877	Impact of Laboratory Charge Display Within the Electronic Health Record Across an Entire Academic Medical Center: Results of a Randomized Controlled Trial. 2017 , 148, 513-522	3
876	Checkpointinhibitoren beim nichtkleinzelligen Lungenkarzinom. 2017 , 23, 838-844	
875	Immuntherapie in der Onkologie. 2017 , 12, 17-33	1
874	PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. 2017 , 8, 58457-58468	35
873	Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients. 2017 , 60, 119-125	8
872	Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours). 2017 , 28, iv158-iv161	
871	The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy. 2017 , 1, 7-7	11
870	Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy. 2017 , 1,	1
869	The Biology of Aging and Cancer: Frailty, Inflammation, and Immunity. 2017 , 23, 201-205	21

868	Cancer Immunotherapy in Older Patients. 2017 , 23, 219-222	4
867	Clinical use of immune checkpoint inhibitors. 2017 ,	
866	Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. 2017 , 2017,	11
865	Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor. 2017 , 8, 2681-2693	14
864	High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma. 2017 , 1, 1306-1308	16
863	A Case of Secondary Adrenocortical Insufficiency Developed due to ACTH Deficiency After Nivolumab Treatment. 2017 , 57, 226-231	0
862	Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma. 2017 , 9, 741-750	14
861	Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. 2017 , 13, 223-236	15
860	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. 2017 , 11, 787	24
859	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. 2017 , 8, 49	314
858	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. 2017 , 8, 730	233
857	Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. 2017 , 8, 410-416	115
856	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. 2017 , 13, 1259-1271	12
855	Treating mutation resistance in non-small cell lung cancer - role of osimertinib. 2017 , 10, 49-56	18
854	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. 2017 , 9,	31
853	Bevacizumab in the treatment of NSCLC: patient selection and perspectives. 2017 , 8, 259-269	25
852	New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab. 2017 , 8, 67-78	20
851	The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. 2017 , 8, 57826-57835	21

850	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. 2017 , 6, 51-71	76
849	Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. 2017 , 8, 1-11	6
848	Immunotherapy Clinical Trials in Neuro-Oncology. 2017 , 181-210	
847	Cancer immunology and melanoma immunotherapy. 2017 , 92, 830-835	5
846	Cost analysis of adverse events associated with non-small cell lung cancer management in France. 2017 , 9, 443-449	4
845	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. 2017 , 7, 1-11	29
844	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. 2017 , 18,	122
843	CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. 2017 , 8, 269	34
842	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. 2017 , 8, 1597	145
841	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. 2017 , 7, 3585-3594	127
840	Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer. 2017 , 9,	41
839	Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. 2017 , 9,	15
838	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. 2017 , 18,	34
837	Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation. 2017 , 8, 66	77
836	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. 2017 , 8, 267	47
835	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. 2017 , 8, 961	70
834	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. 2017 , 8, 1547	80
833	Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. 2017 , 4, 4	24

832	Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. 2017 , 4, 9	11
831	Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib. 2017 , 4, 36	9
830	The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer. 2017 , 7, 33	11
829	Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. 2017 , 7, 38	12
828	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. 2017 , 7, 50	21
827	Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine. 2017 , 7, 52	22
826	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. 2017 , 7, 67	25
825	Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy. 2017 , 7, 114	17
824	Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma. 2017 , 7, 141	14
823	Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. 2017 , 7, 197	18
822	Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"?. 2017 , 7, 205	6
821	Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. 2017 , 2017, 1623679	5
820	A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis. 2017 , 2017, 1093858	12
819	Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. 2017 , 2017, 6012810	9
818	Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. 2017 , 2017, 4719194	53
817	CD80 Expressed by CD8 T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8 T Cells. 2017 , 2017, 7659462	21
816	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. 2017 , 2017, 5618174	8
815	Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer. 2017 , 2017, 1423683	8

814	Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report. 2017 , 57, 191-197	13
813	New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. 2017 , 10, 2513-2526	25
812	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. 2017 , 8, 52889-52900	64
811	Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. 2017 , 8, 1460-1465	9
810	Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology. 2017 , 23, S13-S20	10
809	Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. 2017 , 9, 553-563	11
808	Role of afatinib in the treatment of advanced lung squamous cell carcinoma. 2017 , 9, 147-157	3
807	Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity. 2017 , 8, 57-66	2
806	PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level. 2017 , 8, 3251-3260	17
805	Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. 2017 , 9, 207-213	90
804	Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab. 2017 , 10, 230-234	29
803	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. 2017 , 10, 3697-3708	4
802	Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. 2017 , 8, 48248-48252	65
801	Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. 2017 , 8, 93149-93155	45
800	Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. 2017 , 8, 66491-66503	1
799	Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway. 2017 , 13,	
798	Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma. 2017 , 12, e0179000	2
797	Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. 2017 , 12, e0181598	25

796	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. 2017 , 12, e0183639	2
795	Isolated Adrenocorticotrophic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. 2017 , 56, 2463-2469	27
794	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. 2017 , 6, e1344805	97
793	Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units. 2017 , 12, e0179749	12
792	Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. 2017 , 12, e0186192	33
791	Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. 2017 , 103, 405-421	31
790	Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression. 2017 , 5, 181-185	0
789	Addressing the challenges of applying precision oncology. 2017 , 1, 28	19
788	A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer. 2017 , 17, 683	6
787	Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma. 2017 , 17, 105	27
786	The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. 2017 , 16, 149	165
785	Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. 2017 , 10, 136	33
784	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. 2017 , 10, 174	68
783	Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report. 2017 , 11, 183	6
782	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. 2017 , 5, 66	27
781	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. 2017 , 5, 93	41
780	A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. 2017 , 5, 103	4
779	Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. 2017 , 3, 94	12

778 Immuntherapie thorakaler Tumoren. **2017**, 20, 21-27

777 Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. **2017**, 17, 534 19

776 Immunotherapy in Lung Disease. **2017**, 76, 36-39

775 Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP). **2017**, 56, 2311-2315 18

774 Nivolumab Therapy for Synchronous -Positive Lung Cancer and Gastric Cancer. **2017**, 10, 361-367 3

773 Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. **2017**, 8, 90532-90544 60

772 Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. **2017**, 6, S8-S20 67

771 Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, efficacy and Resistance. **2017**, 06,

770 Recent advances in the management of non-small cell lung cancer. **2017**, 6, 2110 16

769 High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. **2017**, 8, 18021-18030 36

768 Highlights from the cancer Future Horizons in Lung Cancer conference, 1-2 September 2016: Focusing on the future of treatment for NSCLC and SCLC. **2017**, 11, 729 2

767 Nivolumab Maintenance as Monotherapy after Carboplatin Plus Nab- Paclitaxel for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Study Protocol for Feasibility. **2017**, 7,

766 Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer. **2017**, 8, 58199-58209 9

765 Prognostic and Predictive Value of PD-L1 in Patients with Lung Cancer. **2017**,

764 Checkpoint Inhibitors in Nonsmall Cell Lung Cancer. **2017**,

763 Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. **2017**, 8, 61618-61625 8

762 EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. **2017**, 8, 63901-63910 26

761 A rare case of lung carcinoma acquires multidrug-resistant pneumonia radiologically mimicking metastasis caused by nivolumab therapy-associated neutropenia. **2017**, 13, 1375-1377 5

760	An Abscopal Response to Radiation Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer: A Case Report. 2017 , 09,	5
759	PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. 2017 , 8, 98524-98532	37
758	Cancer Immunotherapy. 2017 , 32-65	1
757	Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. 2017 , 8, 8738-8751	87
756	PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. 2017 , 9, E384-E386	14
755	Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer. 2017 , 8, 3190-3197	5
754	Comparative effectiveness and safety of -paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting. 2017 , 8, 179-190	6
753	Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy.. 2021 , 9, 1801	3
752	The foundations of immune checkpoint blockade and the ipilimumab approval decennial.. 2021 ,	15
751	First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes. 2021 , 13,	2
750	Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.. 2021 , 13,	2
749	Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review. 2021 , 11, e047663	
748	Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience.	0
747	Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.. 2021 , 21, 420	2
746	Meta-Analysis of irAEs between Dose of CTLA-4 and PD-1 Inhibitors. 2021 ,	
745	Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung).. 2021 , 45,	0
744	Association of Stage Shift and Population Mortality Among Patients With Non-Small Cell Lung Cancer.. 2021 , 4, e2137508	5
743	Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications.	0

- 742 The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving Research.. **2021**, 23, 1
- 741 A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice.. **2022**, 17, 53-60 0
- 740 Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. **2021**, 4, 258-270 0
- 739 complex lung disease in a patient treated with an immune checkpoint inhibitor: A case report.. **2022**, 16, 37 0
- 738 Relationship between Kita-Kyushu Lung Cancer antigen-1 expression and prognosis of cases with lung squamous cell carcinoma.. **2021**, 10, 5212-5221 0
- 737 ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. **2021**, 4
- 736 Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.. **2022**, 0
- 735 Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.. **2022**, 3, e137 0
- 734 The use of immunotherapy in older patients with advanced non-small cell lung cancer.. **2022**, 106, 102394 1
- 733 Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features.. **2022**, 13, 875093 0
- 732 Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.. **2022**, 82, 649 2
- 731 Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumour.. **2022**, 1
- 730 Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.. **2022**, 13, 862084 0
- 729 Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer.. **2022**, 15, 1
- 728 Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review. 43,
- 727 Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.. **2022**, 22, 407 0
- 726 High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis.. **2022**, 13, 866561 0
- 725 The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. **2022**, 2, 74-92

- 724 Pulmonary Lymphangitis Poses a Major Challenge for Radiologists in an Oncological Setting during the COVID-19 Pandemic.. **2022**, 12, 2
- 723 Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors.. **2022**, 78, 102149
- 722 Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer.. **2022**, 20, 101418 0
- 721 DataSheet_1.pdf. **2021**,
- 720 Table_1.docx. **2021**,
- 719 Data_Sheet_1.PDF. **2019**,
- 718 Image_1.JPEG. **2019**,
- 717 Image_2.JPEG. **2019**,
- 716 Data_Sheet_1.docx. **2020**,
- 715 Data_Sheet_1.docx. **2020**,
- 714 Data_Sheet_1.docx. **2020**,
- 713 Table_1.xlsx. **2019**,
- 712 Table_2.xlsx. **2019**,
- 711 Table_3.xlsx. **2019**,
- 710 Table_4.xlsx. **2019**,
- 709 Table_5.xlsx. **2019**,
- 708 Table_6.xlsx. **2019**,
- 707 Table_7.xlsx. **2019**,

706 Presentation_1.PPTX. 2018,

705 data_sheet_1.docx. 2018,

704 DataSheet_1.csv. 2020,

703 Image_1.tif. 2020,

702 Image_2.tif. 2020,

701 Image_3.tif. 2020,

700 Image_4.tif. 2020,

699 Image_5.tif. 2020,

698 Image_6.tif. 2020,

697 Image_7.tif. 2020,

696 Image_8.tif. 2020,

695 Image_9.tif. 2020,

694 Table_1.docx. 2020,

693 Table_2.docx. 2020,

692 Data_Sheet_1.docx. 2020,

691 Data_Sheet_1.docx. 2020,

690 Data_Sheet_1.docx. 2019,

689 Data_Sheet_1.docx. 2019,

688 Data_Sheet_1.PDF. 2020,

687 Data_Sheet_2.PDF. 2020,

686 Table_1.docx. 2019,

685 Data_Sheet_1.CSV. 2020,

684 Data_Sheet_2.doc. 2020,

683 Image_1.TIF. 2020,

682 Image_2.TIF. 2020,

681 Image_3.TIF. 2020,

680 Image_4.TIF. 2020,

679 Image_5.TIF. 2020,

678 Image_6.TIF. 2020,

677 Image_7.TIF. 2020,

676 Image_8.PNG. 2020,

675 Data_Sheet_1.docx. 2020,

674 Image_1.TIF. 2020,

673 Image_2.TIF. 2020,

672 Table_1.xlsx. 2020,

671 Table_2.xlsx. 2020,

670 Table_3.xlsx. 2020,

669 DataSheet_1.pdf. 2019,

668 Image_1.pdf. 2020,

667 Image_2.pdf. 2020,

666 Data_Sheet_1.docx. 2018,

665 Table_1.DOCX. 2020,

664 Table_1.DOCX. 2020,

663 Data_Sheet_1.doc. 2019,

662 Image_1.tif. 2020,

661 Image_2.tif. 2020,

660 Image_1.TIF. 2019,

659 Image_2.TIFF. 2019,

658 Image_3.TIF. 2019,

657 Table_1.DOCX. 2019,

656 Table_10.DOCX. 2019,

655 Table_11.DOCX. 2019,

654 Table_12.docx. 2019,

653 Table_2.DOCX. 2019,

652 Table_3.DOCX. 2019,

651 Table_4.DOCX. 2019,

650 Table_5.docx. 2019,

649 Table_6.DOCX. 2019,

648 Table_7.DOCX. 2019,

647 Table_8.DOCX. 2019,

646 Table_9.DOCX. 2019,

645 Data_Sheet_1.zip. 2020,

644 Data_Sheet_1.docx. 2020,

643 Image_1.TIF. 2020,

642 Image_2.TIF. 2020,

641 Table_1.DOCX. 2020,

640 Table_2.DOCX. 2020,

639 Table_3.docx. 2020,

638 Data_Sheet_1.docx. 2020,

637 Data_Sheet_1.PDF. 2019,

636 Table_1.XLSX. 2020,

635 Image_1.TIF. 2020,

634 Image_1.TIF. **2020**,

633 Image_2.TIF. **2020**,

632 Image_3.TIF. **2020**,

631 Image_4.TIF. **2020**,

630 Image_5.TIF. **2020**,

629 Table_1.DOCX. **2020**,

628 Table_2.DOCX. **2020**,

627 Table_3.DOCX. **2020**,

626 Table_4.DOCX. **2020**,

625 Table_5.DOCX. **2020**,

624 Data_Sheet_1.PDF. **2019**,

623 A variety of 'exhausted' T cells in the tumor microenvironment.. **2022**, ○

622 [Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer].. **2022**, 25, 46-53

621 The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab.. **2022**, 5, 31-45

620 Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer.. **2022**, 16, 11795549221092747 ○

619 Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival.. **2022**, 15, 56-66 ○

618 Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk.. **2022**, 11, 670-685 ○

617 as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma.. **2022**, 12, 867788 1

616	Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model.. 2022 , 13, 829634	0
615	Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. 2022 , 15, 533	1
614	Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.. 2022 , 13, 869488	0
613	Identification of Novel Prognostic Biomarkers Relevant to Immune Infiltration in Lung Adenocarcinoma.. 2022 , 13, 863796	
612	Current Status and Prospects of Perioperative Treatment with Immune Checkpoint Inhibitors for Resectable Non-Small Cell Lung Cancer. 2022 , 73, 83-86	
611	What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine.. 2022 , 14,	0
610	Characteristics and survival of patients with non-small cell lung cancer treated with immune-checkpoint inhibitors in the real-world: experiences from Bergen, Norway.. 2022 , 1-5	
609	Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.. 2022 , 14,	1
608	A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients. 2022 , 13,	0
607	Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer.. 2022 , 20, 187	1
606	Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability.. 2022 , 9, 874213	0
605	Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study.. 2022 , 14,	2
604	Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. 2022 ,	0
603	MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.. 2022 ,	4
602	Rheumatic immune- and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: a systematic review and meta-analysis.. 2022 , 105403	
601	Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.. 2022 , 13, 874589	1
600	Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis.. 2022 , 17, e0268288	1
599	Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.. 2022 , 168, 50-58	0

598	Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer.. 2022 , 169, 106-122	1
597	CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.. 2022 , 70, 103345	0
596	Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.. 2022 , 12, 876098	0
595	Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy.. 2022 , 42, 1-18	0
594	Different Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy.. 2022 , 2022, 8513747	0
593	Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory.. 2022 ,	
592	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis.. 2022 , 7, 100474	1
591	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).. 2022 , JCO2102660	10
590	The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. 2022 , 13,	1
589	A tumor metastasis-associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity.. 2022 ,	1
588	Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021.. 2022 ,	
587	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.. 2022 , 10,	1
586	An analysis report on the application of immune checkpoint inhibitors after liver transplantation. 2022 , 13, 204062232210993	0
585	Safety and Efficacy of Dostarlimab in Patients with Recurrent/Advanced Non-Small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. 2022 ,	3
584	Revisiting laminin and extracellular matrix remodeling in metastatic squamous cell carcinoma: What have we learned after more than four decades of research?.	0
583	PTBP1 as a Promising Predictor of Poor Prognosis by Regulating Cell Proliferation, Immunosuppression, and Drug Sensitivity in SARC. 2022 , 2022, 1-26	0
582	HLA-I diversity and Tumor Mutational Burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. 2022 ,	0
581	Traitement de 1re ligne des CBNPC m̄tastatiques sans addiction oncoḡhique. 2022 , 14, 1S52-1S67	

580	Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. 13,	1
579	Indonesian consensus on systemic therapies for hepatocellular carcinoma.	
578	Simple IHC reveals complex MMR alternations than PCR assays: Validation by LCM and next-generation sequencing.	0
577	Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation TherapyâProof-of-Concept Animal Study. 2022, 10, 1173	0
576	Combination of Stereotactic Ablative Radiotherapy With Anti-PD-1 in Oligoprogressive Non-Small-Cell Lung Cancer And Melanoma: Results of a Prospective Multicenter Observational Study. 2022,	0
575	FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. 2022,	0
574	Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma. 13,	0
573	Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis.	0
572	Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review. 2022, 20,	1
571	An integrated biomarker of PD-L1 expression and intraepithelial CD8 + T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastases.	0
570	Relationship between PatientsâBaseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. 2022 , 2022, 1-14	0
569	Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer: Exciting New Horizon in Early-Stage Lung Cancer Care.	0
568	Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. 2022, 13, 388-411	1
567	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced NonâSmall-Cell Lung Cancer Previously Treated With ImmunotherapyâLung-MAP S1800A.	4
566	Characterization of m6A Methylation Modification Patterns in Colorectal Cancer Determines Prognosis and Tumor Microenvironment Infiltration. 2022, 2022, 1-17	
565	Immunotherapy and Antivascular Targeted Therapy in PatientsâTreatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge. 2022, 2022, 1-13	
564	Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study. 2022,	0
563	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. 2022, 10, e004440	1

- 562 Neoadjuvant Immunotherapy in Gastrointestinal Cancers â The New Standard of Care?. **2022**, 0
- 561 Targeted therapies in non-small cell lung cancer and the potential role of AI interventions in cancer treatment. 0
- 560 Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for NonâSquamous Non-Small Cell Lung Cancer with Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. **2022**, 100355 0
- 559 Safety evaluation of fixed-dose nivolumab in patients with gastric cancer. **2022**, 5, 0
- 558 Nanotechnology and Immunomodulators in Cancer. **2022**, 125-186 0
- 557 A Brief Introduction to Current Cancer Gene Therapy. **2022**, 1-21 1
- 556 A Meta-Analysis of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer. **2022**, 12, 4692-4699 0
- 555 PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer. **2022**, 29, 107327482211075 0
- 554 Evaluation of Programmed Death Ligand-1 Immunohistochemical Expression and Tumor-Infiltrating Lymphocytes in Different Types of Endometrial Carcinoma. **2022**, 10, 702-708 0
- 553 Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. 12, 0
- 552 First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer. 0
- 551 A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial. 1
- 550 Immune Checkpoint InhibitorâAssociated Myositis. Publish Ahead of Print, 0
- 549 First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. 0
- 548 Novel T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma. **2022**, 22, 0
- 547 Dynamic changes of peripheral NK cells predict outcome in patients with PD-L1 positive Non-Small-Cell Lung Cancer undergoing immune checkpoint inhibitors as second-line therapy. 1-31 0
- 546 Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. 0
- 545 Resveratrol in cancer treatment with a focus on breast cancer. **2022**, 15, 0

544	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. 2022 , 132,	0
543	Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression. 1-13	
542	Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. thoraxjnl-2020-215614	0
541	Treatment Considerations for Patients with Advanced Squamous Cell Carcinoma of the Lung. 2022 ,	1
540	A phase 2 study of docetaxel, ramucirumab, and pembrolizumab for patients with metastatic or recurrent non-small cell lung cancer (NSCLC) who progressed on platinum-doublet and PD-1/PD-L1 blockade.. 2022 ,	0
539	Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACTiVe-2 trial). 2022 , 12, e060431	0
538	Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. 2022 , 13, 448-472	1
537	Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation). 2022 , 186-192	
536	IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression.	1
535	Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy. 2022 , 236, 153990	1
534	Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. 2022 , 176, 103746	
533	Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy. 2022 , 172, 98-106	1
532	Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. 2022 , 23, 101469	
531	Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. 2022 , 172, 85-95	2
530	Role of Lymphocytes in Cancer Immunity and Immune Evasion Mechanisms. 2022 , 159-182	
529	Biomarker Panels and Contemporary Practice in Clinical Trials of Personalized Medicine. 2022 , 549-562	
528	Recent trends in cancer immunotherapy: Pathways and inhibitors. 2022 , 39-50	
527	The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure. 2022 , 34, 64-77	

- 526 ICIs-Related Cardiotoxicity in Different Types of Cancer. **2022**, 9, 203 0
- 525 Network-based machine learning approach to predict immunotherapy response in cancer patients. **2022**, 13, 1
- 524 A review of concurrent chemo/radiation, immunotherapy, radiation planning, and biomarkers for locally advanced non-small cell lung cancer and their role in the development of ECOG-ACRIN EA5181. **2022**,
- 523 Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. Publish Ahead of Print,
- 522 Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study. 0272989X2211076
- 521 Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. 13, 1
- 520 Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives. **2022**, 14, 3138
- 519 The Cognitive Effects of Radiotherapy for Brain Metastases. 12, 1
- 518 Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses. **2022**, 15, 786
- 517 Tumor immunotherapy: Mechanisms and clinical applications. **2022**, 1,
- 516 Upregulation of CCT3 predicts poor prognosis and promotes cell proliferation via inhibition of ferroptosis and activation of AKT signaling in lung adenocarcinoma. **2022**, 23, 0
- 515 Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies. 12, 1
- 514 Racial and ethnic trends and disparities in non-small cell lung cancer. **2022**, 100374
- 513 Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: a key player in tumor immunotherapy. **2022**, 0
- 512 The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer. 0
- 511 Treating advanced lung cancer in older veterans with comorbid conditions and frailty. **2022**,
- 510 Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-27 0
- 509 Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. 0

508	Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology.	0
507	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. 1-14	0
506	The benefit of concurrent chemotherapy with radiotherapy for esophageal cancer is limited in Asian patients aged 80 years or older: a SEER database analysis.	
505	TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy. 2022 , 14, 3382	
504	Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. 2022 , 22,	0
503	HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC. 2022 , 22,	0
502	Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study. <i>annrheumdis-2022-222186</i>	1
501	Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists. 2022 , 29, 4665-4677	0
500	Immunosenescence, inflammaging, and cancer immunotherapy efficacy. 1-12	1
499	Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.	1
498	Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study. 2022 , 14, 3439	2
497	Exploring immunotherapy in colorectal cancer. 2022 , 15,	5
496	Generation, secretion and degradation of cancer immunotherapy target PD-L1. 2022 , 79,	0
495	Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study.	
494	The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis. 12,	0
493	Identification of the KCNQ1OT1/ miR-378a-3p/ RBMS1 Axis as a Novel Prognostic Biomarker Associated With Immune Cell Infiltration in Gastric Cancer. 13,	0
492	Mixed response to cancer immunotherapy is driven by intratumor heterogeneity and differential inter-lesion immune infiltration.	0
491	Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis. 2022 , 171, 3-8	

490 Lung Cancer. **2023**, 57-78

489 Musculoskeletal and Neurological Complications of Check Point Inhibitors. **2023**, 207-214

488 Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer. ○

487 The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. 1

486 Effets indésirables rhumatologiques des inhibiteurs de point de contrôle PD-(L)1 dans le cancer du poumon : revue systématique et méta-analyse. **2022**,

485 Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases. 12, ○

484 A Ferroptosis-Related Gene Signature for Overall Survival Prediction and Immune Infiltration in Lung Squamous Cell Carcinoma. ○

483 Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. 13, ○

482 Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. 13, ○

481 Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial. **2022**, 3, 100689 ○

480 Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access. ○

479 PD-1^{hi} TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC. ○

478 Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients.

477 Positive Correlation of Peripheral CD8⁺ T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. **2022**, 14, 3568 ○

476 Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study. **2022**, 2022, 1-10 ○

475 The association of efficacy with PD-1/PD-L1 inhibition and tumor mutational burden in advanced nonsmall cell lung cancer: A PRISMA-guided literature review and meta-analysis. **2022**, 101, e29676

474 Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres. **2022**, 12, 1149 ○

473 Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. **2022**, 11, 4373

- 472 Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. **2022**, 2022, 1-11
- 471 Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors. **2022**, 22, 1
- 470 Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma. **2022**, 12, 0
- 469 Serum immunoglobulins might be useful predictors of immune-related adverse events after immune checkpoint inhibitor usage in lung cancer. 0
- 468 A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment. 0
- 467 Overexpression of 14-3-3 β primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC. **2022**, 14, 5838-5854 1
- 466 Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis.
- 465 Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. **2022**, 12, 1799 2
- 464 Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. 12, 0
- 463 Progress of immunotherapy in the treatment of pancreatic cancer. 6, 182-191
- 462 Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. 12, 0
- 461 Grade 3&4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. **2022**, 14, 3878 1
- 460 Bayesian sparse modeling to identify high-risk subgroups in meta-analysis of safety data.
- 459 Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review. 0
- 458 Immunotherapy in non-small cell lung cancer: Past, present, and future directions. 12, 2
- 457 Fatal pneumonitis associated with immune checkpoint inhibitors: a study based on 128 cohorts with 26,994 participants.
- 456 Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients. 0
- 455 A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naïve non-small-cell lung cancer: TORG1630. 0

- 454 Regional Variations in Clinical Trial Outcomes in Oncology. **2022**, 20, 879-886.e2 0
- 453 Investigating treatment response and immune profile in association with pattern identification in NSCLC patients scheduled for immune checkpoint inhibitor monotherapy (HARMONY study). **2022**, 3, e0247
- 452 Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. 12, 1
- 451 Ferroptosis-related lncRNAs signature to predict the survival and immune evasion for lung squamous cell carcinoma. 13,
- 450 Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment. **2022**, 5, e2227211 0
- 449 Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients. 12,
- 448 Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis. **2022**, 23, 0
- 447 KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. **2022**, 23, 9391 0
- 446 Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. 12, 0
- 445 Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy. 0
- 444 Sex-specific differences in immunogenomic features of response to immune checkpoint blockade. 12, 0
- 443 Safety and efficacy of immune checkpoint inhibitors in patients with cancer and viral hepatitis: The MD Anderson Cancer Center experience.
- 442 Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. 12, 1
- 441 Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study. **2022**, 33, 752-757
- 440 Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. 12, 2
- 439 Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.
- 438 Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors. 13, 1
- 437 T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. **2022**, 23, 8590 0

436	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. 12,	0
435	Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%. 12,	1
434	The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma.	
433	Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy.	0
432	Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs. 2022, 8,	1
431	Computational design of PD-L1 small molecule inhibitors for cancer therapy.	2
430	Placebo effect in the treatment of non-small cell lung cancer: a meta-analysis. Publish Ahead of Print,	
429	Development of an adenosquamous carcinoma histopathology-selective lung cancer graft model.	
428	Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer. 2022,	0
427	A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. 2022,	0
426	Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programmed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. 12,	
425	Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy. 12,	1
424	A real-world analysis of immune checkpoint inhibitor-based therapy after osimertinib treatment in EGFR-mutant non-small cell lung cancer patients. 2022, 100388	0
423	Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer. 2022,	0
422	Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany. 2022, 172, 65-74	0
421	Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study. 2022, 174, 113-120	0
420	Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study. 2022, 22,	0
419	Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma. 13,	0

418	Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer.	0
417	EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.	0
416	The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. 2022 , 7, 100577	0
415	Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. 2022 , 179, 103806	0
414	Local delivery of gambogic acid to improve anti-tumor immunity against oral squamous cell carcinoma. 2022 , 351, 381-393	1
413	Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy. 2022 , 173, 28-34	0
412	Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. 2022 , 173, 101-106	0
411	First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis. 2022 , 14, 175883592211227	0
410	Ramucirumab in Stage IV non-small-cell lung cancer: Indian data. 2022 , 5, 346	0
409	Multi-omics analysis to identify lung squamous carcinoma lactate metabolism-related subtypes and establish related index to predict prognosis and guide immunotherapy. 2022 , 20, 4756-4770	0
408	Metachronous Primary Lung Cancer Occurring during the Spontaneous Regression of Locally Advanced Lung Cancer: A Rare Case Report. 2022 ,	0
407	Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. 2022 ,	0
406	Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An in vitro study. 2022 , 18, 704	0
405	Long-term follow-up of a patient with synchronous brain metastasis in squamous cell lung cancer. (A clinical case and a literature review). 2022 , 11, 51	0
404	Available Immunotherapy Drugs in Oncology. 2022 , 5-23	0
403	Nervous System Related Adverse Reactions and Management Strategies of Tumor Immune Checkpoint Inhibitors. 2022 , 12, 7964-7971	0
402	Effect of Helicobacter pylori on immunotherapy is gaining more attention. 2022 , 27,	1
401	T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. 2022 , 14, 4246	0

400	Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy. 2022 , 177, 111471	5
399	Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review. 12,	0
398	Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases. 2022 , 10, 2249	0
397	Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review. 12,	0
396	Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways. 12,	0
395	Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study. 2022 , 17, e0274451	0
394	ELEVATE âevaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial. 2022 , 22,	1
393	Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study. 2022 , 22,	1
392	Boosting the Immune ResponseâCombining Local and Immune Therapy for Prostate Cancer Treatment. 2022 , 11, 2793	0
391	Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. 13,	0
390	Modern Clinical Trials in Radiation Oncology.	0
389	Systemic Sclerosis Association with Malignancy.	1
388	Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction. 13,	0
387	Identification of cervical squamous cell carcinoma feature genes and construction of a prognostic model based on immune-related features. 2022 , 22,	0
386	Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer. 13,	0
385	PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials. 2022 , 9, e001294	0
384	Development of a radiolabeled site-specific single-domain antibody positron emission tomography probe for monitoring PD-L1 expression in cancer. 2022 ,	0
383	Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer. 13,	0

- 382 Radiation Recall Pneumonitis: A Rare Syndrome That Should Be Recognized. **2022**, 14, 4642 1
- 381 A retrospective study of second-line chemotherapy combined with immunotherapy in advanced non-small cell lung cancer. 0
- 380 Integration of New Systemic Adjuvant Therapies for Non-Small Cell Lung Cancer: Role of the Surgeon. **2022**, 0
- 379 Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis. **2022**, 54, 2606-2616 0
- 378 Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer. **2022**, 14, 4575 0
- 377 Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma. 0
- 376 Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. **2022**, 14, 4481 0
- 375 Neurology of cancer immunotherapy. 0
- 374 Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma. **2022**, 2022, 1-12 0
- 373 Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis. **2022**, 6, 0
- 372 Thyroid Dysfunction in Non-Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis. 0
- 371 The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis. 13, 0
- 370 Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy. 13, 0
- 369 Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. **2022**, 101, e30151 0
- 368 High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood. **2022**, 10, 2405 0
- 367 Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. 13, 1
- 366 Case report: Anti-PLA2R positive membranous nephropathy associated with atezolizumab. 239936932211254 0
- 365 Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab. **2022**, 14, 4739 1

364	Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. 13,	1
363	CT-based radiomics signature to predict CD8+ tumor infiltrating lymphocytes in non-small-cell lung cancer. 028418512211265	0
362	Molecular Biomarkers of Response to Cancer Immunotherapy. 2022 , 42, 469-484	0
361	Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors. 12,	0
360	Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials. 13,	0
359	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. 13,	0
358	Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade. OF1-OF1	0
357	Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. 12,	0
356	Protocol of the TREASURE study: Thoracic Radiotherapy with Atezolizumab in Small cell lung cancer Extensive disease a randomized, open-label, multicenter phase II trial. 2022 , 22,	0
355	First-in-human study of ONO -4578, an antagonist of prostaglandin E 2 receptor 4, alone and with nivolumab in solid tumors.	0
354	Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial. 2022 ,	0
353	Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Late Phase Oncology Drug Development. 1-34	0
352	Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. 12,	1
351	There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor. 2022 , 17, 1175-1177	0
350	SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.	1
349	Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).	3
348	Efficacy and safety of nivolumab for advanced/recurrent non-small-cell lung cancer: an up-to-date meta-analysis of large-scale phase III randomized controlled trials.	0
347	Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.	2

- 346 Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. 13, 1
- 345 PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma. 13, 0
- 344 Machine learning-based exceptional response prediction of nivolumab monotherapy with circulating microRNAs in non-small cell lung cancer. **2022**, 173, 107-115 0
- 343 Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. **2022**, 550, 215937 1
- 342 Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors. **2022**, 81, 102265 1
- 341 Nivolumab-induced radiation recall pneumonitis in non-small cell lung cancer patients with thoracic radiation therapy. 0
- 340 Incomplete cisplatin regimens in chemoradiation and its effect on outcomes for locally advanced cervical cancer. ijgc-2022-003766 0
- 339 An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer. 0
- 338 History and Evidence of Immune Checkpoint Inhibitors in the Respiratory Field. **2022**, 73, 325-331 0
- 337 Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a multiplex immunohistochemistry-based single-cell analysis. **2022**, 0
- 336 Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study. 1-8 0
- 335 FDG PET/CT in Immune-Related Arthritis in a Patient Treated With Nivolumab. Publish Ahead of Print, 0
- 334 Outcomes of EGFR tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced EGFR-mutated non-small cell lung cancer. 0
- 333 Trends in immune-related adverse events for colorectal cancer: A bibliometric analysis. 12, 0
- 332 Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers. 12, 0
- 331 Immune-infiltrating signature-based classification reveals CD103+CD39+ T cells associate with colorectal cancer prognosis and response to immunotherapy. 13, 0
- 330 Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors. 13, 0
- 329 Update on Immune Checkpoint Inhibitor Enterocolitis. 0

- 328 The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do not Receive Chemoradiation. Publish Ahead of Print, ○
- 327 Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody. **2022**, 119, ○
- 326 A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach. 9, ○
- 325 Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment. 630-642 1
- 324 Traitements systmiques du cancer bronchique non ^ petites cellules chez les sujets g. **2022**, 14, 2S327-2S337 ○
- 323 Metastatic pancreatic neuroendocrine tumors manifest elevated T cell infiltration. ○
- 322 Immunoinfiltration-related gene SERPINE1 is a novel biomarker for diagnosis and prognosis of stomach adenocarcinoma discovered via high throughput transcriptome data mining combined with bioinformatics. ○
- 321 Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitors. ○
- 320 Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study. 13, ○
- 319 Association between genetic variants and the risk of nivolumab-induced immune-related adverse events. ○
- 318 Biomarker-Targeted Therapies in Non-small Cell Lung Cancer: Current Status and Perspectives. **2022**, 11, 3200 ○
- 317 Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. ○
- 316 Ranimation en oncologie ^ l'heure de l'immunothrapie. **2022**, 14, 2S287-2S292 ○
- 315 The Lung Microbiota and Lung Cancer: A Growing Relationship. **2022**, 14, 4813 ○
- 314 Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer. 12, ○
- 313 PD-L1 expression is not a predictive factor for recurrence in resected non-small cell lung cancer Sub-heading: PD-L1 is not a predictive factor for recurrence. ○
- 312 Cancer of the Lung. 1-29 ○
- 311 Immune checkpoint inhibitor for different age patients with NSCLC in efficacy: a systematic review and Meta-analysis. ○

- 310 Algorithm thérapeutique des CBNPC sans mutation addictive. **2022**, 14, 2S165-2S177 ○
- 309 Squamous cell lung cancer: Current landscape and future therapeutic options. **2022**, ○
- 308 Predictive Factors for the Efficacy of Immune Checkpoint Inhibitors Against Lung Cancer. **2022**, 62, 355-362 ○
- 307 More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance. ○
- 306 Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer. ○
- 305 Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer. 13, 2
- 304 Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up. 0272989X2211322 ○
- 303 Liquid Biopsy for Uveal Melanoma. Does It Make Sense?. **2022**, 19, 594-602 ○
- 302 Inmunoterapia en pacientes con cáncer de pulmón y metástasis cerebrales de inicio. **2022**, 25, ○
- 301 Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study. ○
- 300 Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-small Cell Lung Cancer. **2022**, 42, 1956-19742
- 299 The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?. ○
- 298 A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma. 13, ○
- 297 Microsatellite instability detection in breast cancer using drop-off droplet digital PCR. ○
- 296 Pyroptosis predicts immunotherapy outcomes across multiple cancer types. **2022**, 245, 109163 1
- 295 The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. **2022**, 310, 121138 ○
- 294 The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy. **2022**, 156, 113839 ○
- 293 RAS: Circuitry and therapeutic targeting. **2023**, 101, 110505 ○

- 292 Development of models for predicting the objective response of immune checkpoint inhibitor therapy in patients with nonsmall-cell lung cancer. **2022**, 8, 27 ○
- 291 Datele din lumea reală - studiiile clinice pentru evaluarea eficacității noilor terapii oncologice. Rolul studiilor observaționale, cu exemplificare în cancerul pulmonar frântelule mici (NSCLC). **2022**, 3, 23 ○
- 290 Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade. **2017**, 46, 333-338 3
- 289 Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making. 12, ○
- 288 A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus. **2022**, 8, ○
- 287 Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration. **2022**, 2022, 1-15 ○
- 286 PD-L1 expression as predictor of immunotherapy eligibility in penile squamous cell carcinoma patients. 11, 1281 ○
- 285 Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. **2022**, 14, ○
- 284 Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas. 12, ○
- 283 Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). ○
- 282 Imunoterapia en cãncer de pulmã metastãtico. **2022**, 25, ○
- 281 Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence. ○
- 280 The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. 13, ○
- 279 Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses - The ComIT -1 trial. ○
- 278 Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer. ○
- 277 Development of an adenosquamous carcinoma histo pathology-selective lung metastasis model. ○
- 276 CAR T-cells for colorectal cancer immunotherapy: Ready to go?. 13, ○
- 275 Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes. ○

- 274 Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. **2022**, 0
- 273 Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy. **2022**, 1
- 272 PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?. **2022**, 103435, 1
- 271 Emerging evidence of immunotherapy for colorectal cancer. 0
- 270 Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors. **2022**, 82, 100969 0
- 269 Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. 12, 0
- 268 Editorial: Impact of immunotherapy in lung cancer. 12, 0
- 267 Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. **2022**, 20, 0
- 266 Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer. 0
- 265 Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. **2022**, 0
- 264 Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC. 0
- 263 A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer. **2022**, 101, e31751 0
- 262 ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with⁸⁹Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. **2022**, 12, e056708 0
- 261 Multiple Adverse Events of anti-PD1/PDL1 Therapy: A Case- control Study using a Japanese Prescription-diagnostics Database. 0
- 260 An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870). **2022**, 14, 175883592211383 0
- 259 Research Progress of Intestinal Flora in the Treatment of Lung Cancer—Intestinal Flora and Lung Cancer. **2022**, 12, 10933-10941 0
- 258 Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study. **2023**, 175, 17-26 0
- 257 Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions. **2023**, 206, 107093 0

256	The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. 2022,	o
255	Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy. 100-107	o
254	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. 2022, 117, 1917-1932	o
253	Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. 2022, 14, 5931	o
252	Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis. 12,	o
251	Advances in the Lung Cancer Immunotherapy Approaches. 2022, 10, 1963	o
250	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. 2022, 24, 269-304	o
249	Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis. 2022, 12,	1
248	Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network. 13,	o
247	RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis. 12,	o
246	The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-III B Lung Squamous Cell Carcinoma.	o
245	Management of Lung Cancer in the Patient with Interstitial Lung Disease.	o
244	Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer.	o
243	PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. 13,	o
242	Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid TumorsâA Systematic Review of the Literature. 2022, 29, 9428-9436	o
241	Checkpoint inhibitors are a basic science-based, transformative new treatment for lung cancer.	o
240	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. 2022, 22,	o
239	Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. 2022, 23, e552-e561	1

238	Potential Role of Tumor-Derived Exosomes in Non-Small-Cell Lung Cancer in the Era of Immunotherapy. 2022 , 12, 2104	1
237	Immune Checkpoint Inhibitor Therapy in Oncology. 2022 , 4, 579-597	2
236	Local therapy treatment conditions for oligometastatic non-small cell lung cancer. 12,	1
235	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.	0
234	Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report. 2022 , 101, e32076	0
233	A novel diagnostic model for predicting immune microenvironment subclass based on costimulatory molecules in lung squamous carcinoma. 13,	0
232	Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. 2022 , 14, 6146	0
231	Treatment of rheumatic adverse events of cancer immunotherapy. 2022 , 101805	2
230	Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor. 2022 , 7, 100630	0
229	Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC â a systematic review. 12,	0
228	Current status and challenges of immunotherapy in ALK rearranged NSCLC. 12,	0
227	MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors. 2022 , 7, 100646	0
226	Biologic Impact of Green Synthesized Magnetic Iron Oxide Nanoparticles on Two Different Lung Tumorigenic Monolayers and a 3D Normal Bronchial ModelâEpiAirwayTM Microtissue. 2023 , 15, 2	0
225	Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. 2022 , 12, 3157	0
224	Consolidative high-dose thoracic radiotherapy for limited metastatic nonsmall cell lung cancer: Focusing on oligo-progressive disease.	0
223	Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy. 2022 ,	1
222	Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. 2022 , 14, 6148	0
221	Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.	0

- 220 Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis. 12, ○
- 219 Natural history of lung squamous cell brain metastases in patients treated with radiosurgery: a thirty-year experience at a tertiary medical center. ○
- 218 Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. ○
- 217 Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trial. 2022, 22, ○
- 216 MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients. 13, ○
- 215 Two Cases of Subsequent Hepatocellular Carcinoma in ICI-Responsive Non-Small Cell Lung Cancer. 2022, 100448 ○
- 214 Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. 13, ○
- 213 CLINICAL AND TECHNICAL INSIGHTS OF TUMOUR MUTATIONAL BURDEN IN NON-SMALL CELL LUNG CANCER.. 2022, 103891 ○
- 212 T-cell repertoire diversity: friend or foe for protective antitumor response?. 2022, 41, ○
- 211 Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade. 2022, 10, e005670 ○
- 210 The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study. 2022, 14, 6184 ○
- 209 Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-stage Lung Cancer. 2022, ○
- 208 Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma. Volume 16, 4269-4277 ○
- 207 Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology Trials. ○
- 206 Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites. ○
- 205 New Biomarkers Exploration and Nomogram Construction of Prognostic and Immune-Related Adverse Events of Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. ○
- 204 Investigating the Quality of Life for Cancer Patients and Estimating the Cost of Immunotherapy in Selected Cases. 2022, ○
- 203 Model-based meta-analysis of non-small cell lung cancer with standard-of-care PD -1 inhibitors and chemotherapy for early development decision making. ○

- 202 Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study. 12, ○
- 201 Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018. **2023**, 23, ○
- 200 Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors. ○
- 199 Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. ○
- 198 Mechanisms of Resistance to Immunotherapies in Cancer. **2023**, 1-30 ○
- 197 Baseline radiomic signature to estimate overall survival in patients with non-small cell lung cancer. **2023**, ○
- 196 Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer. **2023**, ○
- 195 A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. **2023**, 15, 329 ○
- 194 Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. 13, ○
- 193 Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. 13, ○
- 192 Analyse finale de l'étude EVIDENS par région française : survie et tolérance en vie réelle à 3 ans des patients atteints d'un cancer bronchique non à petites cellules (CBNPC) traité par nivolumab. **2023**, 15, 130 ○
- 191 DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden. 12, ○
- 190 Atezolizumab induced new-onset type 1 diabetes mellitus. 107815522311516 ○
- 189 Upregulation of complement proteins in lung cancer cells mediates tumor progression. 12, ○
- 188 Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies. **2023**, 108347 ○
- 187 Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer. **2023**, 13, 167 1
- 186 Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. 14, ○
- 185 Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. **2023**, ○

- 184 Strahlentherapie und Immuntherapie. **2023**, 1-20 ○
- 183 A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer. ○
- 182 The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. ○
- 181 The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. ○
- 180 Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research. 12, ○
- 179 Combined hypophysitis and type 1 diabetes mellitus related to immune checkpoint inhibitors. ○
- 178 CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis. 11, e14668 ○
- 177 Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer. **2023**, 35, 100382 ○
- 176 Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer. **2023**, 857, 147177 ○
- 175 Anti-Programmed Death Receptor 1 Signalling Immunotherapy as a Part of Curative Intent Strategies for Stages I-III Non-Small Cell Lung Cancer. 109-116 ○
- 174 The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis. **2022**, 101, e32393 ○
- 173 Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. ○
- 172 Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer. ○
- 171 Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas. 1-5 ○
- 170 Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer. **2022**, 27, ○
- 169 Atypical Response in Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Radiographic Patterns and Clinical Value of Local Therapy. **2023**, 15, 180 ○
- 168 Cancer trials as opportunities to serve and learn from individuals with human immunodeficiency virus. ○
- 167 Novel Bispecific Aptamer Targeting PD-1 and Nucleolin for Cancer Immunotherapy. ○

- 166 Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis. **2023**, 24, 599 ○
- 165 Telomere Status of Advanced Non-Small-Cell Lung Cancer Offers a Novel Promising Prognostic and Predictive Biomarker. **2023**, 15, 290 ○
- 164 PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer. ○
- 163 The influence of drug-eluting beads transarterial chemoembolization on serum levels of soluble programmed cell death protein-1 in advanced hepatocellular carcinoma patients. ○
- 162 First-line Immunotherapy and Clinically Meaningful Survival Benefits for the Oldest Adults With Lung Cancer. ○
- 161 Use of Programmed Cell Death Protein 1 (PD-1) Inhibitor Therapy in HIV-infected Patients with Advanced Cancer:a single-center study from China. ○
- 160 Tumor immunology. **2023**, 245-452 ○
- 159 Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. **2023**, 11, e005924 ○
- 158 Prediction of Risk and Clinical Outcome of cuproptosis in Lung Squamous carcinoma. ○
- 157 [18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. **2023**, 1-40 ○
- 156 Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma. **2023**, 13, ○
- 155 Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. 1
- 154 Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting. **2023**, 15, 175883592311528 ○
- 153 Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection â systematic review. **2023**, ○
- 152 Immunotherapy for older patients with cancer. **2023**, 17, 37-46 ○
- 151 Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics. **2023**, 13, ○
- 150 Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis. 12, ○
- 149 Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. 13, ○

- 148 Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. ○
- 147 Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases is not associated with an increased risk of radiation necrosis over non-concurrent treatment: An international multicenter study of 657 patients. **2023**, ○
- 146 Upregulated SSB Is Involved in Hepatocellular Carcinoma Progression and Metastasis through the Epithelial-Mesenchymal Transition, Antiapoptosis, and Altered ROS Level Pathway. **2023**, 2023, 1-16 ○
- 145 Immunotherapy: Targeting Cancer Cells. **2023**, 179-217 ○
- 144 Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC. **2023**, 15, 175883592311563 ○
- 143 Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors. **2023**, 15, 1382 ○
- 142 Predictive value of 18F-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer. 14, ○
- 141 A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer. **2023**, 23, ○
- 140 Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment. ○
- 139 Liposomal ATM siRNA delivery for enhancing triple-negative breast cancer immune checkpoint blockade therapy. 088532822311621 ○
- 138 Efficacy and safety of combined immunotherapy and stereotactic radiosurgery in NSCLCBM patients and a novel prognostic nomogram: A real-world study. 13, ○
- 137 Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. **2023**, 117, 109881 ○
- 136 Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies. 14, ○
- 135 Biomarkers of response to immunotherapy in early stage non-small cell lung cancer. **2023**, 184, 179-196 ○
- 134 Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic. **2023**, 83, 101004 ○
- 133 Therapeutic efficacy of plant-produced Nivolumab in transgenic C57BL/6-hPD-1 mouse implanted with MC38 colon cancer. **2023**, 38, e00794 ○
- 132 Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade. ○
- 131 Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer. **2023**, 33, 189-196 ○

- 130 Qualitative analysis of PD-L1 expression in non-small-cell lung cancer based on chest CT radiomics. **2023**, 84, 104815 ○
- 129 Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. **2023**, 4, 113-129.e7 ○
- 128 Immunology and immunotherapy of cholangiocarcinoma. 1
- 127 Metabolic dialogs between B cells and the tumor microenvironment: Implications for anticancer immunity. **2023**, 556, 216076 ○
- 126 Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. **2023**, 12, 218 ○
- 125 Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India. ○
- 124 Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens. ○
- 123 IgG4 expression and IgG4/IgG ratio in the tumour invasion front predict long-term outcomes for patients with intrahepatic cholangiocarcinoma. **2023**, ○
- 122 A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab. ○
- 121 Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. **2023**, 178, 116-122 ○
- 120 Expression and prognosis of ICOS and its ligand in Chinese lung adenocarcinoma population. ○
- 119 Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial. **2023**, 178, 96-102 ○
- 118 Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis. 13, ○
- 117 Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. **2023**, 14, ○
- 116 Characterization of the immune cell landscape in CRC: Clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC. 13, ○
- 115 Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. **2023**, 153, 40039 ○
- 114 CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma. **2023**, 9, 195-207 ○
- 113 Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. **2023**, 15, 1076 ○

- 112 Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis. **2023**, 23, ○
- 111 Real-world evidence of nivolumab for non-small-cell lung cancer in a developing country. 108155892211478 ○
- 110 The safety profile of EGFR/ALK-TKIs administered immediately before or after ICIs in advanced NSCLC. **2023**, 116, 109787 ○
- 109 Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. **2023**, 11, 508 ○
- 108 Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. **2023**, 4, 100474 ○
- 107 Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis. 14, ○
- 106 Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. **2023**, 9, e13725 ○
- 105 Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. **2023**, 30, 2366-2387 ○
- 104 Unexpected curative effect of PD-1 inhibitor in gastric cancer with brain metastasis: A case report. 13, ○
- 103 Optimising Cancer Immunotherapy: Challenges and Opportunities. 26-43 ○
- 102 Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer. 14, ○
- 101 Immunotherapy associated central nervous system complications in primary brain tumors. 13, ○
- 100 Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis. ○
- 99 Exosomal microRNAs in cancer: Potential biomarkers and immunotherapeutic targets for immune checkpoint molecules. 14, ○
- 98 The past, present, and future of immunotherapy for colorectal cancer. **2023**, 40, ○
- 97 The Efficacy and Hemorheological Indexes of Ginseng and Its Active Components for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. **2023**, 2023, 1-15 ○
- 96 Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing. **2023**, 38, 100884 ○
- 95 Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives. **2023**, 2, 65-78 ○

- 94 Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy. ○
- 93 Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application. 13, ○
- 92 Lung cancer immunotherapy: progress, pitfalls, and promises. **2023**, 22, ○
- 91 Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer. ○
- 90 Abdominal Aortic Aneurysm Repair in Patients with Concomitant Cancer: A Literature Review. 170853812311501
- 89 Developing an m5C regulator-mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer. 14, ○
- 88 Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. **2023**, 11, e006464 ○
- 87 Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy. 13, ○
- 86 MicroRNA in lung cancer—a novel potential way for early diagnosis and therapy. ○
- 85 Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. **2023**, 102, e32899 ○
- 84 Blocking CD47-SIRPβ Signal Axis as Promising Immunotherapy in Ovarian Cancer. **2023**, 30, 107327482311597 ○
- 83 Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL). **2023**, 4, 100484 ○
- 82 MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. **2023**, ○
- 81 The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer. **2023**, 11, 705 ○
- 80 CD169 + sinus macrophages in regional lymph nodes do not predict mismatch-repair status of patients with colorectal cancer. ○
- 79 Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials. **2023**, 13, 1
- 78 New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors. **2023**, 24, ○
- 77 Current status and future perspectives of bispecific antibodies in the treatment of lung cancer. **2023**, 136, 379-393 ○

- 76 Case report: Spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: Exceptional tumor micro-environment. 14, ○
- 75 Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. **2023**, 12, 1833 ○
- 74 Correlation of 18F-FDG PET/CT metabolic parameters with the expression of immune biomarkers in the tumour microenvironment in lung adenocarcinoma. **2023**, ○
- 73 CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. **2023**, 14, ○
- 72 Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. **2023**, 184, 103954 ○
- 71 Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. 14, ○
- 70 Prognostic Significance of Circulating Basophil Counts in Patients Who Underwent Esophagectomy for Esophageal Cancer. ○
- 69 Radiomics models based on multisequence MRI for prediction of PD-1/PD-L1 expression in hepatocellular carcinoma. ○
- 68 Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer. ○
- 67 Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. **2023**, 12, 832 ○
- 66 Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer. 13, ○
- 65 Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity. **2023**, 11, e006462 ○
- 64 Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis. **2023**, 55, 808-819 ○
- 63 Current Advances in Immune Checkpoint Therapy. ○
- 62 Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients. ○
- 61 Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China. **2023**, 7, 273-284 ○
- 60 Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy. **2023**, 12, 851 ○
- 59 Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma. ○

- 58 Post-progression survival in advanced non-small cell lung cancer treated with anti-PD-1/PDL-1 monotherapy: progression after durable clinical benefit versus primary resistance. ○
- 57 Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. **2023**, 11, e006433 ○
- 56 Anti-PD-(L)1 therapy of non-small cell lung cancer—a summary of clinical trials and current progresses. **2023**, 9, e14566 ○
- 55 Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥50% in Patients Treated in Quebec—University Teaching Hospitals (DALP-First Study). **2023**, 30, 3251-3262 ○
- 54 Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions. ○
- 53 Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test. **2023**, 36, 100159 ○
- 52 Expression and Clinical Significance of PD-L1 and PD-1 in Thymic Carcinoma. **2023**, 13, 3702-3708 ○
- 51 Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study. 13, ○
- 50 Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors. ○
- 49 The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. 14, ○
- 48 Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. **2023**, ○
- 47 Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. **2023**, 16, ○
- 46 Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice. **2023**, 12, 2409 ○
- 45 Combined chemo-immuno-photothermal therapy based on ursolic acid/astragaloside IV-loaded hyaluronic acid-modified polydopamine nanomedicine inhibiting the growth and metastasis of non-small cell lung cancer. **2023**, 11, 3453-3472 ○
- 44 Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer. **2023**, 15, 1909 ○
- 43 Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study. 14, ○
- 42 Immune Checkpoint Inhibitor (ICI) with PD-1 And PD-L1. 36, 1062-1066 ○
- 41 Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC. 13, ○

- 40 Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. ○
- 39 Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT). **2023**, 8, 101192 ○
- 38 Onionin A inhibits small-cell lung cancer proliferation through suppressing STAT3 activation induced by macrophages-derived IL-6 and cell-cell interaction with tumor-associated macrophage. **2023**, 36, 1068-1080 ○
- 37 Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma. 14, ○
- 36 Application status and future prospects of the PDX model in lung cancer. 13, ○
- 35 Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma. **2023**, 35, 166-177 ○
- 34 Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study. **2023**, 13, 877 ○
- 33 Date de tip real world privind utilizarea nivolumabului în cancerul pulmonar nonmicrocelular avansat încolo de linia a doua. Experiență noastră în România imediat după rambursarea imunoterapiei prin sistemul național de sănătate. **2023**, 1, 32 ○
- 32 Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy. **2023**, 14, ○
- 31 Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer. ○
- 30 Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. **2023**, 14, ○
- 29 Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. 14, ○
- 28 Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice. **2023**, 23, ○
- 27 Feasibility and safety of shortened hypofractionated high-dose palliative lung radiotherapy – a retrospective planning study. **2023**, 108, 102559 ○
- 26 Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer: AJR Expert Panel Narrative Review. ○
- 25 Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report. ○
- 24 Vimentin expression correlates with immune-checkpoint inhibitor efficacy in non-small cell lung cancer. ○
- 23 Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. ○

- 22 Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. **2023**, 11, 1073 ○
- 21 Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. **2023**, 23, ○
- 20 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194 ○
- 19 Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. ○
- 18 Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. **2023**, 15, 1252 ○
- 17 Immunotherapy in Lung Cancer: Current Landscape and Analysis of Biomarkers. **2023**, 13, 37-43 ○
- 16 A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer. **2023**, 40, ○
- 15 Radiation Biology of Lung Cancer. **2023**, ○
- 14 The Value of Peripheral Blood Index in the Evaluation of Curative Effect of Advanced Non-Small Cell Lung Cancer. **2023**, 13, 5979-5988 ○
- 13 Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. **2023**, 24, 7577 ○
- 12 Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia. **2023**, 13, ○
- 11 Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. **2023**, 154470 ○
- 10 Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis. ○
- 9 Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. **2023**, 24, 7592 ○
- 8 Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial. ○
- 7 Telomerase deficiency and dysfunctional telomeres in the lung tumor microenvironment impair tumor progression in NSCLC mouse models and patient-derived xenografts. ○
- 6 Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness. 14, ○
- 5 Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy. ○

- 4 Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors. 14,
- 3 A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitors in solid tumors: The OTHERS study. 2023, 187, 104016
- 2 Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.
- 1 Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo. 2023, 120-121, 108351